Hong Kong Reference Framework for Hypertension Care for Adults in Primary Care Settings

Revised Edition December 2018

Developed by:
-task force on conceptual model and preventive protocols

With the professional advice of:
-Department of Health

Supported by:
-Hong Kong Academy of Medicine
-Hong Kong College of Community Medicine
-The Hong Kong College of Family Physicians
-Faculty of Medicine, The Chinese University of Hong Kong
-Li Ka Shing Faculty of Medicine, The University of Hong Kong
-Hong Kong Medical Association
-The Association of Licentiates of Medical Council of Hong Kong
-The Hong Kong Medical Council
-Hong Kong Society of Endocrinology, Metabolism and Reproduction
-Hong Kong Doctors Union
-Hong Kong College of Cardiology
-Hong Kong Society of Endocrinology, Metabolism and Reproduction
-Diabetes Hongkong
-Hong Kong College of Family Physicians
-The University of Hong Kong

First published: 2010
## Content

Preface to the First Edition

Key To Evidence Statements And Grades Of Recommendations

Statement Of Intent

Chapter 1. Epidemiology

Chapter 2. Population-based Intervention And Life Course Approach

Chapter 3. Role Of Primary Care In The Management Of Hypertension

Chapter 4. Patient Education

Chapter 5. Aim Of The Framework

Chapter 6. Component 1: Prevention Of Hypertension - Adoption Of A Healthy Lifestyle

Chapter 7. Component 2: Early Identification Of People With Hypertension

Chapter 8. Component 3: Clinical Care Of Adults With Hypertension

8.1 Initial assessment and investigation of the hypertensive patient

8.2 Treatment of adults with hypertension

8.3 Target values for blood pressure lowering

8.4 Follow up and monitoring

8.5 Referral

Chapter 9. Component 4: Patient Empowerment

Chapter 10. Future Direction

Appendix 1. Smoking Cessation Services

Acknowledgments

References

### Modules

<table>
<thead>
<tr>
<th>Module</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Module 1</td>
<td>Framework For Population Approach In The Prevention And Control Of Hypertension Across The Life Course</td>
</tr>
<tr>
<td>Module 2</td>
<td>Blood Pressure Measurement</td>
</tr>
<tr>
<td>Module 3</td>
<td>Secondary Hypertension</td>
</tr>
<tr>
<td>Module 4</td>
<td>Evaluation For All Newly Diagnosed Hypertensive Patients</td>
</tr>
<tr>
<td>Module 5</td>
<td>Dietary Intervention</td>
</tr>
<tr>
<td>Module 6</td>
<td>Exercise Recommendations To People With Hypertension</td>
</tr>
<tr>
<td>Module 7</td>
<td>Drug Treatment For People With Hypertension</td>
</tr>
<tr>
<td>Module 8</td>
<td>Annual Assessment</td>
</tr>
<tr>
<td>Module 9</td>
<td>Lipid Management in Hypertensive Patients</td>
</tr>
</tbody>
</table>
Enhancing primary care is one of the proposals put forward in the Healthcare Reform Consultation Document “Your Health, Your Life” and has received broad public support during the first stage of public consultation conducted in 2008. In recognition of the broad support for the proposals, the Working Group on Primary Care (Working Group) under the Health and Medical Development Advisory Committee chaired by the Secretary for Food and Health was reconvened to discuss and provide strategic recommendations on enhancing and developing primary care in Hong Kong.

Four Task Forces have been established to study specific proposals set out in the Healthcare Reform Consultation Document. One of them is the Task Force on Conceptual Model and Preventive Protocols (Task Force). The Task Force makes recommendations to the Working Group on conceptual models that are evidence based with associated reference frameworks for use in the local primary care settings. The Task Force is also responsible for promulgating, maintaining and revising the models and frameworks, and the strategies to promote their adoption.

After a series of discussions with stakeholders, the Task Force has developed a basic conceptual model for the management of chronic disease using a population approach across life-course. It is based on the recognition that we need a comprehensive and continuous approach to care focused on the person to meet their needs and address their risks. The reference frameworks cover primary prevention and lifestyle changes, assessment of high risk groups, early detection and management of diseases as well as ensuring the quality of care for more complicated conditions or disabilities within the community. The need to coordinate inputs from multi-disciplinary teams, engage patients and interface with the community and other sectors is also highlighted.

To date, two reference frameworks, one on diabetes and the other on hypertension, have been developed. These reference frameworks consist of a core document supplemented by a series of different modules addressing various aspects of disease management which aim to -
(a) provide a common reference to guide and co-ordinate care to patients from all healthcare professionals across different sectors in Hong Kong for the provision of continuous, comprehensive and evidence-based care for diabetes and hypertension in the community;
(b) empower patients and their carers; and
(c) raise public’s awareness on the importance of preventing and properly managing these two major chronic diseases.

Drawing on international experience and best evidence, these frameworks provide general reference for practice in primary care settings to support the policy of promoting primary care within Hong Kong. However, since clinical practice and patient engagement need to keep pace with scientific advancements, in order to ensure the latest medical developments and evidence are reflected in the frameworks to provide reference for best practice, two Clinical Advisory Groups under the Task Force have been established to review and update the reference frameworks on a regular basis. The Clinical Advisory Groups are composed of experts from academia, professional organisations, private and public primary care sector and patient groups who are members of the groups in their own right, not representing organisations.

To facilitate the promulgation and adoption of the reference frameworks, support and endorsement from healthcare professionals across different sectors in Hong Kong has been and will continue to be very important. We hope that the adoption of the reference frameworks will improve patient care by facilitating co-ordination of their care, strengthen management continuity, promote evidence based effective and efficient practice, empower patients and their carers as well as enhancing public awareness about the prevention and management of these two major chronic diseases in our community.

Professor Sian GRIFFITHS
Convenor
Task Force on Conceptual Model and Preventive Protocols
## Key To Evidence Statements And Grades Of Recommendations

### Levels of Evidence

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1++</td>
<td>High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias</td>
</tr>
<tr>
<td>1+</td>
<td>Well conducted meta-analysis, systematic reviews of RCTs, or RCTs with a low risk of bias</td>
</tr>
<tr>
<td>1-</td>
<td>Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias</td>
</tr>
<tr>
<td>2++</td>
<td>High quality systematic reviews of case control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal</td>
</tr>
<tr>
<td>2+</td>
<td>Well conducted case control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal</td>
</tr>
<tr>
<td>2-</td>
<td>Case control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal</td>
</tr>
<tr>
<td>3</td>
<td>Non-analytic studies, e.g. case reports, case series</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion</td>
</tr>
</tbody>
</table>

# Scottish Intercollegiate Guidelines Network (SIGN) classification.
## Grades of Recommendation

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results</td>
</tr>
<tr>
<td>B</td>
<td>A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+</td>
</tr>
<tr>
<td>C</td>
<td>A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2++</td>
</tr>
<tr>
<td>D</td>
<td>Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+</td>
</tr>
</tbody>
</table>
Statement Of Intent

The framework is constructed from global evidence of best practice. As with all guidance it aims to support decision making, recognising that all patients are unique and have their own needs. The Task Force endeavours to provide accurate and up-to-date information. The frameworks provide support for decision making and as such are not mandatory. They should not be construed as within any legal framework, rather as guidance for professional practice. Standards of care for individual patients are determined on the basis of all the facts and circumstances involved in a particular case. They are subject to change as scientific knowledge and technology advances and patterns of care evolve. Management of diseases must be made by the appropriate primary care practitioners responsible for clinical decisions regarding a particular treatment procedure or care plan. The responsible primary care practitioners should only arrive at a particular treatment procedure or care plan following discussion with the patient on the diagnostic and treatment choices available.
Chapter 1. Epidemiology

Hypertension means high blood pressure. Systolic blood pressure ≥ 140mm Hg or diastolic blood pressure ≥ 90mm Hg is considered high. If hypertension is not well controlled and treated, it will increase the risk of cardiac failure, coronary heart disease, renal failure and stroke.

Hypertension is prevalent in Hong Kong. The Population Health Survey 2014 - 15 of the Department of Health revealed that around 27% of the population aged 15 or above had increased blood pressure. The prevalence increased with advancing age, with 4.5% among those aged 15 to 24 and up to 64.8% for those aged 65 to 84 (Table 1). Moreover, among those 27% with increased blood pressure, around half (13.2%) were unaware of their condition, only found to have their blood pressure raised during the survey.

<table>
<thead>
<tr>
<th>Age Group (Years)</th>
<th>Self-reported, doctor diagnosed hypertension (%)</th>
<th>Undiagnosed but measured (%)</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-24</td>
<td>1.0</td>
<td>3.4</td>
<td>4.5</td>
</tr>
<tr>
<td>25-34</td>
<td>0.4</td>
<td>5.2</td>
<td>5.6</td>
</tr>
<tr>
<td>35-44</td>
<td>3.9</td>
<td>11.3</td>
<td>15.2</td>
</tr>
<tr>
<td>45-54</td>
<td>10.5</td>
<td>16.2</td>
<td>26.7</td>
</tr>
<tr>
<td>55-64</td>
<td>27.0</td>
<td>19.4</td>
<td>46.4</td>
</tr>
<tr>
<td>65-84</td>
<td>43.8</td>
<td>20.9</td>
<td>64.8</td>
</tr>
<tr>
<td>All age groups</td>
<td>14.6</td>
<td>13.2</td>
<td>27.7</td>
</tr>
</tbody>
</table>
Chapter 2. Population-based Intervention And Life Course Approach

Hypertension, like other chronic health conditions, poses a formidable challenge to the healthcare delivery system. Traditional care services organised to respond to acute patient problems cannot adequately serve the needs of persons with chronic diseases such as hypertension. A more systematic approach to care is required. In addition, a multidisciplinary team approach has consistently shown to be effective in achieving blood pressure control of patients, as reported in clinical trials and many practice settings. In recent years, population-based approach in the control and management of chronic diseases is emphasised. This approach seeks to embrace the whole spectrum of the problem from health promotion, disease prevention and treatment to rehabilitation. To achieve this overarching goal, a proactive approach covering primary, secondary and tertiary levels of prevention is adopted. This involves promotion of healthy behaviours to reduce disease risk, early disease detection, and quality management with the ultimate goal to reduce the incidence of complications and associated morbidities and mortality in the population.

The risks of developing chronic diseases including hypertension and cardiovascular diseases are influenced by factors acting at all stages of life. The effects of these modifiable risk factors accumulate with increasing age, especially in predisposed individuals. Major chronic diseases often share common risk factors e.g. undesirable environmental conditions, social deprivation, unhealthy dietary habit, physical inactivity, alcohol misuse and smoking. Thus, it is necessary and advantageous to adopt an integrated and life course approach in the prevention and control of chronic diseases based on the needs and risks of different population sub-groups to prevent the onset of diseases and reduce the rate of disease progression. Module 1 summarises a comprehensive approach that involves different hypertension prevention or proactive management strategies that are most relevant for the different stages of the life course.
Primary care is the first point of contact in the healthcare system and is easily accessible to the majority of the population. With support and training, primary care practitioners form an invaluable workforce in the community to deliver coordinated care to hypertensive patients, especially those with clinically stable conditions and to identify high risk subjects for referral to other experts. By applying the principles of family medicine and working in partnership with other healthcare professionals such as dietitians, nurses, occupational therapists, optometrists, pharmacists and physiotherapists, primary care practitioners are in a prime position to provide patient-centered, continuing and comprehensive care taking into account individual patients’ needs and values.

In the management of chronic diseases such as hypertension, it is desirable for primary care practitioners to provide ongoing education to reduce risks, diagnose disease early, assess patients’ needs, monitor treatment responses and adherence, and identify treatment barriers such as patients’ concerns and misperceptions. Furthermore, they could provide holistic care by treating concurrent illnesses and co-morbidities, addressing their patients’ psychosocial concerns, empowering them to change behaviour and enabling them to develop coping skills for special occasions, e.g. marriage, pregnancy, travelling and sick day management. Due to the large scope of services involved in the primary, secondary and tertiary prevention of hypertension and associated complications, multidisciplinary care targeting at interfaces between different sectors is essential. Therefore, close collaboration and coordination between primary and secondary care teams are required.
Chapter 4. Patient Education

Patient education is the cornerstone of hypertension management where patients (and their carers) are empowered with appropriate knowledge and skills to live with the disease. Patients with hypertension must be given basic knowledge about the nature, consequences and treatment of the disease as well as their rights and responsibilities in terms of access to care, adherence to recommended treatment and self-management. Primary care practitioners and other care professionals should help dispel misconceptions and address patients’ concerns about the disease and its treatment, e.g. fear for long-term medication, and emphasise the positive aspects of the disease in terms of risk awareness, adoption of a healthy lifestyle and regular surveillance by a health care team.

Chapter 5. Aim Of The Framework

The Reference Framework for Hypertension Care in Adults in Primary Care Setting provides an updated evidence-based approach and recommends core interventions to influence current practice with a view to reducing the burden of long-term complications, including cardiovascular diseases. The Framework also aims to provide adults with or at risk of developing hypertension with a reference for better self-management and proactive disease control.

The Framework has adopted the levels of evidence and grades of recommendations proposed by the Scottish Intercollegiate Guidelines Network (SIGN). In general, grade A recommendation is supported by level 1 evidence, whilst levels 2 and 3 evidence are considered as fair evidence.
There are two complementary approaches to reducing the incidence of hypertension in the population:

- The ‘population approach’, the aim of this approach is to reduce the average level of risk for developing hypertension across the entire population. The interventions required include:
  - increasing physical activity levels,
  - improving diet and nutrition,
  - preventing excess dietary salt intake, and
  - preventing and reducing overweight and obesity.

- The ‘individual-based/high-risk approach’, which aims to identify those at increased risk of developing hypertension, offer them appropriate advice on how to reduce the risk, and support them to lose weight and increase their physical activity levels. People with multiple risk factors for developing hypertension should also be given advice and support opportunistically to minimise their risk.

**Recommendations**

Advise individuals at increased risk of developing hypertension and patients with hypertension to maintain optimal body weight, restrict dietary salt intake, abstain from smoking and practise healthy lifestyles.

Supporting evidence

- Individuals with above-optimal blood pressure, including stage 1 hypertension (refer to Table 1), can make multiple lifestyle changes such as weight loss, sodium reduction, increased physical activity and dietary changes, to help lower their blood pressure and reduce cardiovascular risk.\(^4\)
Routine blood pressure measurement is of value in detecting hypertension and also provides a useful record of baseline blood pressure in normotensive patients. Classification of blood pressure and recommendations on the frequency of blood pressure screening are depicted in Table 2. For accurate blood pressure measurement, please refer to Module 2.

**Recommendations**

**Blood pressure measurement in all adults from 18 years of age at least every 2 years.**

Table 2. Classification Note 1 of blood pressure with reference to statement from World Health Organization 1a and guideline from European Society of Cardiology / European Society of Hypertension 1b, and recommendation for corresponding frequency of blood pressure review and action.

<table>
<thead>
<tr>
<th>Blood pressure classification</th>
<th>Initial Blood Pressure (mmHg)</th>
<th>Recommended minimum review period</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Optimal</strong></td>
<td>Systolic</td>
<td>Diastolic</td>
<td></td>
</tr>
<tr>
<td>&lt;120</td>
<td>&lt;80</td>
<td>Recheck in 2 years</td>
<td>Encourage to adopt healthy lifestyle</td>
</tr>
<tr>
<td><strong>Normal</strong></td>
<td>120-129</td>
<td>80-84</td>
<td>Recheck in 1 year</td>
</tr>
<tr>
<td><strong>High normal</strong></td>
<td>130-139</td>
<td>85-89</td>
<td>Recheck in 6 months</td>
</tr>
<tr>
<td><strong>Grade 1 hypertension</strong></td>
<td>140-159</td>
<td>90-99</td>
<td>Confirm within 2 months</td>
</tr>
</tbody>
</table>
| **Grade 2 hypertension**     | 160-179 | 100-109             | Evaluate within 1 month      | • Treat within 1 month  
 • Lifestyle modification |
| **Grade 3 hypertension**     | ≥180     | ≥110                | Further evaluation within 1 week | • If high blood pressure is confirmed, drug treatment should be commenced  
 • May warrant urgent referral if patient presents features suggestive of malignant hypertension (Refer to Box 2)  
 • Lifestyle modification |
Note 1. The classification is based on the average of 3 or more properly measured seated blood pressure readings, at least 1 week apart on office visit.

Note 2. If systolic and diastolic categories are different, follow recommendations for shorter review period.

Note 3. Modify review period according to reliable information about past blood pressure measurements, other cardiovascular risk factors, or target organ diseases.

Note 4. When considering a diagnosis of hypertension, measure blood pressure in both arms:

- If the difference in readings between arms is more than 20 mmHg, repeat the measurements.
- If the difference in readings between arms remains more than 20 mmHg on the second measurement, measure subsequent blood pressure in the arm with the higher reading.
Effective treatment of hypertension can prevent or delay many of its complications, especially cardiovascular and renal complications. Medication for the control of blood pressure also plays an important role. More importantly, the management of hypertension depends on the commitment of the patient to participate proactively in self-management, adopting healthy lifestyle practices, and prompt detection and treatment of emerging cardiovascular risk factors and complications.

8.1 Initial assessment and investigation of patient with hypertension

Upon diagnosis, primary care practitioners should perform comprehensive assessment to assess co-existing cardiovascular risk factors or other problems that may affect prognosis and treatment (Box 1). Module 3 denotes the findings suspicious of secondary hypertension. Module 4 provides details regarding the assessment and investigations for individual newly diagnosed with hypertension.

### Box 1 Cardiovascular risk factors

- Cigarette smoking
- Obesity
- Physical inactivity
- Dyslipidaemia
- Diabetes mellitus
- Microalbuminuria or estimated GFR < 60 ml/min
- Age (older than 55 for men, 65 for women)
- Family history of essential hypertension and premature cardiovascular disease (men under 55 or women under 65)
8.2 Treatment of adults with hypertension

The aim of the treatment is to obtain maximal reduction in overall cardiovascular risk which requires:

- Correcting risk factors e.g. lifestyle modification, smoking cessation
- Maintaining good blood pressure control, and
- Monitoring potential complications and timely referral to specialist care when indicated.

8.2.1 Lifestyle modification

Adoption of a healthy lifestyle is critical for the prevention of high blood pressure and is an indispensable part of the management of those with hypertension\(^8\). Lifestyle modifications including healthy eating, dietary salt restriction, regular physical activity and stress management can reduce blood pressure, enhance antihypertensive drug efficacy, and reduce cardiovascular risk.

8.2.1.1 Weight control

Recommendations

Encourage overweight and obese\(^a\) hypertensive patients to lose weight.

---

\(^a\) According to the BMI classification for Chinese adults adopted by the Department of Health, overweight is defined as BMI from 23.0 kg/m\(^2\) to less than 25.0 kg/m\(^2\), while obesity is defined as BMI 25.0 kg/m\(^2\) or above.
Supporting evidence

- A study showed that weight loss of 9.5 lbs (4.3 kg) among overweight adults reduced systolic blood pressure by 3.7 mmHg and diastolic blood pressure by 2.7 mm Hg at six months\(^9\). Another study showed that an 18-month weight loss intervention program was significantly associated with a 77% long term reduction in the incidence of hypertension among subjects with blood pressure in the high normal range\(^10\).

8.2.1.2 Healthy eating

Recommendations

Increase consumption of fruits and vegetables to five portions per day, and reduce total and saturated fat consumption.

Supporting evidence

- Patient with high blood pressure is benefited by adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan\(^11\) which is a diet rich in fruits, vegetables, and low in fat dairy products with a reduced content of dietary cholesterol as well as saturated and total fat. (Module 5)
8.2.1.3  Dietary sodium restriction

Recommendations

Encourage all hypertensive patients to reduce salt intake to less than five grams (around one teaspoon of table salt) per day and not to use added salt.

Supporting evidence

- Systolic and diastolic blood pressure could be lowered by 6.7mmHg and 3.5mmHg respectively through decreasing daily dietary salt intake from 9 grams to 3 grams among a group of adults with blood pressure exceeding 120/80mmHg\textsuperscript{11,12,13}. (Module 5)

8.2.1.4  Physical activity

Recommendations

Advise hypertensive patients to increase level of physical activity and take regular exercises.

Supporting evidence

- Regular aerobic exercises among hypertensive individuals were associated with 4.94mmHg reduction of systolic blood pressure and 3.73mmHg reduction of diastolic blood pressure\textsuperscript{14}. (Module 6)
8.2.1.5 Alcohol consumption

Recommendations

Reduce alcohol intake in hypertensive patients to no more than two standard drinks per day\(^b\) for men and one standard drink per day for women.

Supporting evidence

- Alcohol reduction was associated with a significant reduction in mean systolic and diastolic blood pressure. A dose-response relationship was found between the mean percentage of alcohol consumption and mean blood pressure reduction\(^{15}\).

- In large population-based studies, the incidence of hypertension is increased among those who drink more than 3 drinks per day, either in a linear dose-response relationship or with a threshold wherein smaller quantities are associated with a modest decrease. Chronically, the incidence of hypertension is increased among women who drink more than two drinks per day and among men who drink more than three per day\(^{16,17}\). The cessation of heavy drinking is usually followed by significant fall in blood pressure\(^{18}\).

For more information on alcohol screening and brief intervention, please visit the following web page from the Department of Health https://www.change4health.gov.hk/en/alcoholfails/

---

\(^{b}\) Each standard drink contains 10 grams of pure alcohol. Defining one standard drink as 10 grams of pure alcohol, it equates to about 250 ml of regular beer at 5% of alcohol content, one small glass (100 ml) of wine at 12% alcohol content, or one pub measure (30ml) of hard liquor at 40% of alcohol content.
8.2.1.6  *Stop smoking*

**Recommendations**

**Encourage all hypertensive patients to stop smoking.**

**Supporting evidence**

- Smoking cessation is the most effective, immediate way to reduce cardiovascular risk. The pressor effect of smoking could be partly responsible for the major increase in stroke and coronary disease among smokers, as well as for the apparent resistance to antihypertensive therapy\(^{19,20}\).

- Smoking exerts a major pressor effect on ambulatory blood pressure monitoring\(^{21}\). The use of smokeless tobacco and cigars may also raise blood pressure\(^{22}\). Smoking cessation could reduce the overall cardiovascular risk as there was a clear dose-response relationship between the number of cigarettes smoked per day and risk of developing both coronary heart disease and stroke\(^{23}\).

If assistance is needed, please refer to Appendix 1 for more information on smoking cessation services.

For details regarding the practical approach to help patients quit smoking, please refer to the Module on Smoking Cessation in Primary Care Settings available at www.pco.gov.hk/english/resource/files/Module_on_Smoking_Cessation.pdf
8.2.2 Drug treatment

Therapy begins with lifestyle modification, and if blood pressure goal is not achieved, drug treatment must often be considered in addition. The choice of drug treatment should take into account the specific indications and contraindications. (Module 7)

Recommendations

Consider to start drug treatment in patients with sustained systolic blood pressures $\geq 140\text{mmHg}$ or diastolic blood pressures $\geq 90\text{mmHg}$ despite lifestyle modification for 6 months or if target organ damage is present.

Supporting evidence

- The Hypertension Optimal Treatment (HOT) randomised trial showed that intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events$^{34}$.

8.3 Target values for blood pressure lowering

The relationship between blood pressure and cardiovascular risk is continuous. In general, the higher the risk of the individual patient, the more aggressive blood pressure lowering is indicated.
8.3.1 Individual with uncomplicated hypertension

Recommendations

The initial goal of therapy for uncomplicated hypertensive patients is blood pressure below 140/90mmHg; and for individuals who can tolerate, the blood pressure should be targeted to 130/80mmHg or lower.\(^c\)

Supporting evidence

- Lowering systolic blood pressure to <140 mmHg reduced the relative risk of all major cardiovascular outcomes (including mortality); similar benefits were seen when systolic blood pressure was lowered to <130 mmHg. The latter was still true when the achieved systolic blood pressure in the comparator group was 130 - 139 mmHg. Achieved diastolic blood pressure to either 89 - 80 mmHg or <80 mmHg showed a reduction in all types of cardiovascular outcomes compared with higher diastolic blood pressure values.\(^{24a}\)

8.3.2 Patient with hypertension and diabetes

Recommendations

Target blood pressure is below 130/80 mmHg.

Supporting evidence

- Patients with hypertension and type 2 diabetes in the tighter blood pressure control group had far fewer cardiovascular system (CVS) events than those at the less tight control group\(^{25}\).
- The subgroup of diabetes patients randomised to lowest diastolic blood pressure group (<80 mmHg) had the most significant reductions in CVS events\(^{25}\). An even lower diastolic BP was found to be beneficial in diabetes patients

---

\(^c\) Lower blood pressure is advisable for young or overweight/obese patients, smokers and patients with other cardiovascular risk factors.
8.3.3 **Patient with hypertension and chronic kidney diseases**

**Recommendations**

**Target blood pressure is below 130/80 mmHg.**

Supporting evidence

- Patients with chronic kidney disease in the low target blood pressure group had a significantly slower reduction in glomerular filtration rate (GFR) decline compared with patients assigned to the high target blood pressure group\(^{26}\).
- The risks for kidney failure and the composite outcome of kidney failure and all-cause mortality were significantly lower in the low target blood pressure group\(^{27}\).
- Systolic blood pressure range of 110-129 mmHg was associated with the lowest risk of kidney disease progression in patients with urine protein excretion > 1g/day\(^{28}\).

8.4 **Follow up and monitoring**

After initiating antihypertensive drug treatment, most patients should be followed up within 2 weeks until the blood pressure goal is achieved. More frequent visits may be indicated for patients with systolic blood pressure \(\geq 160\)mmHg or diastolic blood pressure \(\geq 100\)mmHg or with complications.

Once the blood pressure goal is achieved, the follow-up interval may be extended to 6-12 weeks depending on the patient’s condition and the doctor’s assessment.
To help monitor patient progress, it is recommended to have a clinical data base to capture key criteria such as:

- blood pressure,
- risk profile status and trend
- drug regimen,
- compliance,
- side effect,
- end organ assessment result, and
- specialist care.

In addition to routine follow-up, annual assessment is recommended for all patients under antihypertensive treatment. Module 8 provides details regarding annual assessment for people with hypertension.

### 8.5 Referral

Most patients with uncomplicated hypertension can be managed by their primary care practitioners. However, certain situations may warrant referral to specialists for assessment (Box 2).

#### Box 2. Referral to Specialists

<table>
<thead>
<tr>
<th>Immediate referral to hospital setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Malignant hypertension</td>
</tr>
<tr>
<td>» DBP &gt; 130mmHg</td>
</tr>
<tr>
<td>» Heavy proteinuria</td>
</tr>
<tr>
<td>» Papilloedema</td>
</tr>
<tr>
<td>» Encephalopathy</td>
</tr>
<tr>
<td>- Accelerated hypertension: DBP &gt; 130mmHg and retinal hemorrhage</td>
</tr>
<tr>
<td>- Persistent BP &gt; 220/120mmHg despite rest or drug treatment</td>
</tr>
<tr>
<td>- Pregnancy:</td>
</tr>
<tr>
<td>» BP ≥ 140/90mmHg and &gt; 20 weeks gestation</td>
</tr>
<tr>
<td>» Signs and symptoms of pre-eclampsia (headache, proteinuria, oedema)</td>
</tr>
</tbody>
</table>
### Referral to specialist

- Suspected secondary hypertension
- Patients aged 30 or below
- Hypertension in pregnancy of less than 20 weeks gestation without signs and symptoms of pre-eclampsia
- Patients with progressive complications e.g. target organ damage
- Medication problems for example:
  - severe drug reaction
  - treatment resistance
  - multiple drug intolerance
  - multiple drug contraindication
- Pregnancy
Empowerment of patient requires an increase of their awareness about what they can do to prevent diseases occurrences in the first instance such as living healthier lifestyles, the need for regular health checks and also the need for self-maintenance, thereby sharing with their doctors the management of their chronic diseases such as diabetes and hypertension. Certainly, the healthcare professional needs to develop a working alliance with their patients to enhance and support their capacity for self-maintenance and self-care.

Patients should understand the nature of hypertension, the need for long-term medication and healthy lifestyle maintenance, the consequence of poor blood pressure control, and treatment options. They should also be informed of the possible side effects of drugs and to seek medical advice should they occur. The aim of patient education is to empower patients with the necessary knowledge and skills so that they can take charge of their own health, to adopt a healthy lifestyle and have better adherence to the management protocols (Box 3).

Written information should be given to patients if available e.g. pamphlets on healthy eating, techniques for taking blood pressure.

**Box 3. Patient’s Knowledge, Skill and Behaviour Checklist**

<table>
<thead>
<tr>
<th>Patient with hypertension should know and practise:</th>
</tr>
</thead>
<tbody>
<tr>
<td>● Know the nature of the disorder</td>
</tr>
<tr>
<td>● Understand hypertension can be asymptomatic</td>
</tr>
<tr>
<td>● Know the risk of complications and, in particular, the importance of blood pressure monitoring</td>
</tr>
<tr>
<td>● Set individual target of treatment</td>
</tr>
<tr>
<td>● Know individual lifestyle requirements</td>
</tr>
<tr>
<td>● Know importance of exercise in treatment and practise regularly</td>
</tr>
<tr>
<td>● Know self-monitoring of blood pressure, and the meaning of blood pressure readings, as well as what action needs to be taken</td>
</tr>
<tr>
<td>● Know the possible side effects of drugs they are taking and seek doctor’s advice promptly should they occur</td>
</tr>
<tr>
<td>● Need to regularly follow up with your doctors</td>
</tr>
</tbody>
</table>
Chapter 10. Future Direction

Through developing and promoting the various reference frameworks, coupled with other system changes to the service delivery model for primary care, it is hoped to bring about a paradigm shift that would put a much greater emphasis on preventive care.

The reference framework is an evolving entity that will be extended and updated over time. The key to the usefulness of this reference framework is its adaptability to local structures, environments and needs. To achieve the goal of providing preventive services most effectively requires a multidisciplinary approach with concerted effort from all the stakeholders in primary care. It also involves a system adopting a more proactive approach that comprises the whole spectrum of primary, secondary and tertiary levels of prevention. It is hoped that the reference frameworks would:

1) Promote the family doctor concept which emphasises continuity of care, holistic care and patient-centred care.

2) Put greater emphasis on prevention of diseases and illnesses.

3) Facilitate primary care professionals to collaborate with other professionals to provide co-ordinated services.

4) Achieve collaboration and interfacing of service providers in the community through an integrated system.
## Appendix 1. Smoking Cessation Services

<table>
<thead>
<tr>
<th>Service</th>
<th>Organisation</th>
<th>Telephone number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrated Smoking Cessation Hotline of the Department of Health</td>
<td>Department of Health</td>
<td>1833 183 (Press 1)</td>
</tr>
<tr>
<td>Smoking Counselling and Cessation Hotline</td>
<td>Hospital Authority</td>
<td>1833 183 (Press 3), 2300 7272</td>
</tr>
<tr>
<td>HKU Youth Quitline</td>
<td>The University of Hong Kong</td>
<td>1833 183 (Press 5), 2855 9557</td>
</tr>
<tr>
<td>Tung Wah Smoking Cessation Hotline</td>
<td>Tung Wah Group of Hospitals</td>
<td>1833 183 (Press 2), 2332 8977</td>
</tr>
<tr>
<td>Pok Oi Smoking Cessation Service using Traditional Chinese Medicine</td>
<td>Pok Oi Hospital</td>
<td>1833 183 (Press 4), 2607 1222</td>
</tr>
</tbody>
</table>
Acknowledgments

The Working Group on Primary Care gratefully acknowledges the invaluable contribution of the Members of the Task Force on Conceptual Model and Preventive Protocols and the Clinical Advisory Group on the Hong Kong Reference Framework for Hypertension Care in Adults in Primary Care Setting in the development of the Reference Framework.

Members of the Working Group on Primary Care of the Health and Medical Development Advisory Committee (2010)

<table>
<thead>
<tr>
<th>Position</th>
<th>Name and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman:</td>
<td>Dr York CHOW Yat-ngok Secretary for Food and Health</td>
</tr>
<tr>
<td>Alternate Chairman:</td>
<td>Prof Gabriel M LEUNG Under Secretary for Food and Health</td>
</tr>
<tr>
<td>Food and Health Bureau:</td>
<td>Ms Sandra LEE Suk-yee Permanent Secretary for Food and Health (Health)</td>
</tr>
<tr>
<td>Members:</td>
<td>Ms Elaine CHAN Sau-ho Vice President, Group &amp; Credit Insurance, Health Services Department, American International Assurance Company (Bermuda) Limited</td>
</tr>
<tr>
<td></td>
<td>Dr CHAN Wai-man Assistant Director of Health (Family &amp; Elderly Health Services), Department of Health</td>
</tr>
<tr>
<td></td>
<td>Dr Joseph CHAN Woon-tong Deputy Medical Superintendent &amp; Head, Department of Women’s Health and Obstetrics, Hong Kong Sanatorium &amp; Hospital</td>
</tr>
<tr>
<td></td>
<td>Dr Lincoln CHEE Wang-jin Chief Executive Office, Quality Health Care Asia Limited</td>
</tr>
<tr>
<td></td>
<td>Dr Raymond CHEN Chung-i Chief Executive Office, Hong Kong Baptist Hospital</td>
</tr>
<tr>
<td></td>
<td>Mr CHEUNG Tak-hai Vice-chairperson, Alliance for Patients’ Mutual Help Organizations</td>
</tr>
</tbody>
</table>
### Acknowledgments

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr CHU Leung-wing</td>
<td>Consultant &amp; Chief Division of Geriatric Medicine, Queen Mary Hospital and Grantham Hospital, Hospital Authority</td>
</tr>
<tr>
<td>Dr Daniel CHU Wai-sing</td>
<td>Chief of Service and Cluster Service Coordinator (Family Medicine and Primary Healthcare) and Deputy Cluster Service Director (Community Services), Hong Kong East Cluster, Hospital Authority</td>
</tr>
<tr>
<td>Ms Ivis CHUNG Wai-yee</td>
<td>Chief Manager (Allied Health), Hospital Authority</td>
</tr>
<tr>
<td>Ms Sylvia FUNG Yuk-kuen</td>
<td>Chief Manager (Nursing) /Chief Nurse Executive, Hospital Authority</td>
</tr>
<tr>
<td>Prof Sian GRIFFITHS</td>
<td>Professor of Public Health &amp; Director, School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>Ms Agnes HO Kam-har</td>
<td>Head of Medical and Group Life, HSBC Insurance (Asia) Limited</td>
</tr>
<tr>
<td>Dr Ronnie HUI Ka-wah</td>
<td>Chief Finance Officer and Executive Director, Town Health International Holdings Co., Ltd.</td>
</tr>
<tr>
<td>Prof Cindy LAM Lo-kuen</td>
<td>Professor and Head, Department of Family Medicine and Primary Care, The University of Hong Kong</td>
</tr>
<tr>
<td>Ms Connie LAU Yin-hing</td>
<td>Chief Executive, Consumer Council</td>
</tr>
<tr>
<td>Dr Paco LEE Wang-yat</td>
<td>Specialist in Family Medicine, St. Paul’s Hospital</td>
</tr>
<tr>
<td>Dr Sigmund LEUNG Saiman</td>
<td>President, Hong Kong Dental Association</td>
</tr>
<tr>
<td>Dr Donald LI Kwok-tung</td>
<td>Specialist in Family Medicine, Director, Bauhinia Foundation Research Centre</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td><strong>Prof LIU Liang</strong></td>
<td>Dean, School of Chinese Medicine, Hong Kong Baptist University</td>
</tr>
<tr>
<td><strong>Dr LO Su-vui</strong></td>
<td>Director (Strategy and Planning), Hospital Authority</td>
</tr>
<tr>
<td><strong>Dr Louis SHIH Tai-cho</strong></td>
<td>Specialist in Dermatology &amp; Venereology</td>
</tr>
<tr>
<td><strong>Dr TSE Hung-hing</strong></td>
<td>Immediate Past President, The Hong Kong Medical Association</td>
</tr>
<tr>
<td><strong>Dr Gene TSOI Wai-wang</strong></td>
<td>Immediate Past President, The Hong Kong College of Family Physicians</td>
</tr>
<tr>
<td><strong>Dr Nelson WONG Chi-kit</strong></td>
<td>Head, Corporate Medical Scheme Service, Dr Vio &amp; Partners</td>
</tr>
<tr>
<td><strong>Prof Thomas WONG Kwok-shing</strong></td>
<td>Vice President (Management), The Hong Kong Polytechnic University</td>
</tr>
<tr>
<td><strong>Prof George WOO</strong></td>
<td>Dean, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University</td>
</tr>
<tr>
<td><strong>Dr YEUNG Chiu-fat</strong></td>
<td>President, Hong Kong Doctors Union</td>
</tr>
</tbody>
</table>

**Members of the Task Force on Conceptual Model and Preventive Protocols (2010)**

<table>
<thead>
<tr>
<th>Convener:</th>
<th>Members:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prof Sian GRIFFITHS</strong></td>
<td>Professor of Public Health &amp; Director, School of Public Health and Primary Care, The Chinese University of Hong Kong</td>
</tr>
<tr>
<td><strong>Dr Alfred AU Si-yan</strong></td>
<td>Service Director (Community Care), New Territories West Cluster, Hospital Authority</td>
</tr>
<tr>
<td><strong>Prof Cecilia CHAN Lai-wan</strong></td>
<td>Si Yuan Professor in Health and Social Work; Director, Centre on Behavioral Health; Professor, Department of Social Work and Social Administration, The University of Hong Kong</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dr CHAN Wai-man</td>
<td>Assistant Director of Health (Family &amp; Elderly Health Services), Department of Health</td>
</tr>
<tr>
<td>Dr Joseph CHAN Woon-tong</td>
<td>Deputy Medical Superintendent &amp; Head, Department of Women's Health and Obstetrics, Hong Kong Sanatorium &amp; Hospital</td>
</tr>
<tr>
<td>Dr Lincoln CHEE Wang-jin</td>
<td>Chief Executive Office, Quality Health Care Asia Limited</td>
</tr>
<tr>
<td>Mr CHEUNG Tak-hai</td>
<td>Immediate Past Chairman &amp; Vice-chairperson, Alliance for Patients’ Mutual Help Organizations</td>
</tr>
<tr>
<td>Dr Regina CHING Cheuk-tuen</td>
<td>Assistant Director of Health (Health Promotion), Department of Health</td>
</tr>
<tr>
<td>Dr CHU Leung-wing</td>
<td>Consultant in-charge, Hong Kong West Cluster Geriatrics Service, Queen Mary Hospital, Hospital Authority</td>
</tr>
<tr>
<td>Dr Daniel CHU Wai-sing</td>
<td>Cluster Services Coordinator (Family Medicine &amp; Primary Healthcare) &amp; Consultant, Hong Kong East Cluster, Hospital Authority</td>
</tr>
<tr>
<td>Ms Ivis CHUNG Wai-yee</td>
<td>Chief Manager (Allied Health), Hospital Authority</td>
</tr>
<tr>
<td>Ms Sylvia FUNG Yuk-kuen</td>
<td>Chief Manager (Nursing) /Chief Nurse Executive, Hospital Authority</td>
</tr>
<tr>
<td>Dr Ronnie HUI Ka-wah</td>
<td>Finance (Executive) Director, Town Health International Holdings Co., Ltd</td>
</tr>
<tr>
<td>Prof Cindy LAM Lo-kuen</td>
<td>Professor and Head, Department of Family Medicine and Primary Care, The University of Hong Kong</td>
</tr>
<tr>
<td>Dr Augustine LAM Tsan</td>
<td>Chief of Service, Family Medicine, Prince of Wales Hospital; Cluster Co-ordinator (Community Partnership), New Territories East Cluster; Cluster Co-ordinator (Family Medicine), New Territories East Cluster, Hospital Authority</td>
</tr>
<tr>
<td>Name</td>
<td>Position and Affiliation</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dr Sigmund LEUNG Saiman</td>
<td>President, Hong Kong Dental Association</td>
</tr>
<tr>
<td>Dr Shirley LEUNG Sze-lee</td>
<td>Principal Medical &amp; Health Officer (Family Health Service), Department of Health</td>
</tr>
<tr>
<td>Dr LEUNG Ting-hung</td>
<td>Consultant Community Medicine (Non-Communicable Disease) and Head, Surveillance &amp; Epidemiology Branch, Centre for Health Protection, Department of Health</td>
</tr>
<tr>
<td>Dr Donald LI Kwok-tung</td>
<td>Director, Bauhinia Foundation Research Centre</td>
</tr>
<tr>
<td>Prof LIU Liang</td>
<td>Dean, School of Chinese Medicine, Hong Kong Baptist University</td>
</tr>
<tr>
<td>Dr LO Su-vui</td>
<td>Director (Strategy and Planning), Hospital Authority</td>
</tr>
<tr>
<td>Dr Louis SHIH Tai-cho</td>
<td>Specialist in Dermatology &amp; Venereology</td>
</tr>
<tr>
<td>Dr TSE Hung-hing</td>
<td>Immediate Past President, Hong Kong Medical Association</td>
</tr>
<tr>
<td>Dr Gene TSOI Wai-wang</td>
<td>Immediate Past President, The Hong Kong College of Family Physicians</td>
</tr>
<tr>
<td>Prof Thomas WONG Kwok-shing</td>
<td>Vice President (Management), The Hong Kong Polytechnic University</td>
</tr>
<tr>
<td>Dr Marcus WONG Mong-sze</td>
<td>Associate Consultant, Family Medicine and Primary Healthcare, Hong Kong East Cluster, Hospital Authority</td>
</tr>
<tr>
<td>Prof George WOO</td>
<td>Dean, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University</td>
</tr>
<tr>
<td>Dr YEUNG Chiu-fat</td>
<td>President, Hong Kong Doctors Union</td>
</tr>
</tbody>
</table>
Acknowledgments

| Dr Betty YOUNG Wan-yin | Cluster Chief of Service (Paediatrics & Adolescent Medicine), Hong Kong East Cluster, Hospital Authority; Chief of Service (Paediatrics & Adolescent), Pamela Youde Nethersole Eastern Hospital |

Members of the Clinical Advisory Group on Reference Framework for Hypertension Care in Adults in Primary Care Setting (2010)

| Convener: | Prof Sian GRIFFITHS, Professor of Public Health & Director, School of Public Health and Primary Care, The Chinese University of Hong Kong |

<p>| Members: | Dr Amy CHAN Kit-ling, Private General Practitioner |
| Mr CHEUNG Tak-hai | Vice-Chairman, Alliance of Patient Mutual Help Organizations |
| Mr POON Kwok-fan | Chairman, The Hong Kong Stroke Association |
| Ms Caroline CHIU Wai-hing | Ward manager of New Territories East Cluster Family Medicine &amp; General Outpatient Clinic, Fanling Family Medicine Centre |
| Dr Gabriel CHOI Kin | President, Hong Kong Medical Association |
| Dr Daniel CHU Wai-sing | Cluster Services Coordinator (Family Medicine &amp; Primary Healthcare) &amp; Consultant, Hong Kong East Cluster, Hospital Authority |
| Dr Ronnie HUI Ka-wah | Chief Finance Officer and Executive Director, Town Health International Holdings Company Limited |
| Dr Linda HUI Yin-fun | Consultant (Elderly and Family Health Service), Department of Health |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof Cindy LAM Lo-kuen</td>
<td>Professor and Head, Department of Family Medicine and Primary Care, The University of Hong Kong</td>
</tr>
<tr>
<td>Dr LAU Chu-pak</td>
<td>Specialist in Cardiology</td>
</tr>
<tr>
<td>Dr LAU Suet-ting</td>
<td>Co-Chairperson, Central Committee on Cardiac Service, Hospital Authority; Consultant, Medicine and Geriatrics, Princess Margaret Hospital</td>
</tr>
<tr>
<td>Prof Philip LI Kam-tao</td>
<td>Head of Division, Division of Nephrology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>Dr LI Sum-wo</td>
<td>Immediate Past President, The Association of Licentiates of Medical Council of Hong Kong</td>
</tr>
<tr>
<td>Dr Luke TSANG Chiu-yee</td>
<td>Consultant (Family Medicine), Department of Health</td>
</tr>
<tr>
<td>Prof TSE Hung-fat</td>
<td>Professor in Cardiology, Department of Medicine, The University of Hong Kong</td>
</tr>
<tr>
<td>Dr Bernard WONG Bun-lap</td>
<td>Specialist in Cardiology</td>
</tr>
<tr>
<td>Prof Martin WONG Chi-sang</td>
<td>Associate Professor, School of Public Health and Primary Care, The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>Dr Chris WONG Kwok-yiu</td>
<td>President-Elect, Hong Kong College of Cardiology</td>
</tr>
<tr>
<td>Dr Michelle WONG Man-ying</td>
<td>Associate Consultant in Family Medicine and Primary Health Care, HK East Cluster, Hospital Authority</td>
</tr>
<tr>
<td>Dr Alexander WONG Shou-pang</td>
<td>Specialist in Cardiology</td>
</tr>
<tr>
<td>Dr YEUNG Chiu-fat</td>
<td>President, Hong Kong Doctors Union</td>
</tr>
<tr>
<td>Professor YU Cheuk-man</td>
<td>Head, Division of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong</td>
</tr>
</tbody>
</table>
The on-going updating and development of new modules under this reference framework is supported by the **Advisory Group on Hong Kong Reference Framework for Care of Diabetes and Hypertension in Primary Care Settings** since 2016. The Department of Health gratefully acknowledges the invaluable support and contribution of Members of this Advisory Group.

**Members of the Advisory Group on Hong Kong Reference Framework for Care of Diabetes and Hypertension in Primary Care Settings (2016-2019)**

<table>
<thead>
<tr>
<th>Role and Field</th>
<th>Name and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Representative from the field of family medicine, The Chinese University of Hong Kong</td>
<td>Prof Martin WONG Chi-sang (Convenor)</td>
</tr>
<tr>
<td>Representative from the field of endocrinology, diabetes and metabolism, The Chinese University of Hong Kong</td>
<td>Prof Juliana CHAN Chung-ngor</td>
</tr>
<tr>
<td>Representative from the field of endocrinology, diabetes and metabolism, The University of Hong Kong</td>
<td>Prof Kathryn TAN Choon-beng</td>
</tr>
<tr>
<td>Representative from the Society of Endocrinology, Metabolism and Reproduction</td>
<td>Dr NG Ying-wai</td>
</tr>
<tr>
<td>Representative from the Hong Kong College of Cardiology</td>
<td>Dr LAU Suet-ting</td>
</tr>
<tr>
<td>Representative from the field of cardiology, The Chinese University of Hong Kong</td>
<td>Prof Alex LEE Pui-wai</td>
</tr>
<tr>
<td>Representative from the field of cardiology, The University of Hong Kong</td>
<td>Prof TSE Hung-fat</td>
</tr>
<tr>
<td>Representative from the Hong Kong Dietitians Association</td>
<td>Miss Sylvia LAM See-way</td>
</tr>
<tr>
<td>Representative from the field of family medicine, The University of Hong Kong</td>
<td>Dr Colman FUNG Siu-cheung</td>
</tr>
<tr>
<td>Representative from the Hong Kong Medical Association</td>
<td>Prof Cindy LAM Lo-kuen (from June 2018)</td>
</tr>
<tr>
<td>Representative from the Hong Kong Doctors Union</td>
<td>Dr HO Chung-ping</td>
</tr>
<tr>
<td>Representative from the Association of Licentiates of Medical Council of Hong Kong</td>
<td>Dr CHEUNG Hon-ming</td>
</tr>
<tr>
<td>Representative from the field of endocrinology, diabetes and metabolism, Hospital Authority</td>
<td>Dr LAU Ip-tim Dr Jenny LEUNG Yin-yan (from June 2018)</td>
</tr>
<tr>
<td>Representative from the field of cardiology, Hospital Authority</td>
<td>Dr YUE Chiu-sun</td>
</tr>
<tr>
<td>Representative from the Professional Development and Quality Assurance, Department of Health</td>
<td>Dr Kinson LAU Kin-sang</td>
</tr>
</tbody>
</table>
References


## Module 1  Framework for Population Approach in the Prevention and Control of Hypertension across the Life Course

<table>
<thead>
<tr>
<th>Age group</th>
<th>Lifestyle advice</th>
<th>Risk assessment</th>
<th>Screening</th>
<th>Disease management</th>
<th>Complication monitoring</th>
<th>Rehabilitation care</th>
</tr>
</thead>
</table>
| Antenatal | ● A balanced diet  
● Regular intake of carbohydrates  
● Lower in fat  
● Plenty of fruits and vegetables  
● Physically active | ● Monitor weight gain | ● Watch out for pre-eclampsia | ● Early antenatal care  
● Blood pressure and lipid control  
● Self-care | ● Monitor fetal growth  
● Obstetric complications in women |  |
| Infancy   | ● Breast feeding  
● Avoid obesity  
● Regular exercise  
● Adequate sleep | ● Monitor weight gain |  |  |  |  |
| Childhood | ● Abstain from smoking  
● Regular exercise  
● Healthy eating habit  
● Limit sodium intake | ● Monitor BMI | ● Watch out for secondary hypertension | ● Treat secondary hypertension  
● Monitor growth and development  
● Carer education and support |  |  |
| Adulthood | ● Abstain from smoking  
● Smoking cessation for smokers  
● Healthy eating habit  
● Limit sodium intake  
● Weight management  
● Regular exercise  
● Limit alcohol consumption | ● Monitor BMI  
● Monitor abdominal circumference  
● Family history of diabetes | ● Measure blood pressure for all individuals aged ≥ 18 every 2 years¹  
● More frequent blood pressure measurement for individuals with moderate or high risk of vascular disease¹  
● Opportunistic measurement of blood pressure at all clinic visits | ● Blood pressure and lipid control  
● Monitor the adverse effect of drug treatment  
● Self-care | ● Target organ damage, e.g. nephropathy, neuropathy, cardiovascular complications  
● Hypotension  
● Malignant hypertension |  |
### Module 1  
Framework for Population Approach in the Prevention and Control of Hypertension across the Life Course

<table>
<thead>
<tr>
<th>Age group</th>
<th>Lifestyle advice</th>
<th>Risk assessment</th>
<th>Screening</th>
<th>Disease management</th>
<th>Complication monitoring</th>
<th>Rehabilitation care</th>
</tr>
</thead>
</table>
| Elderly   | ● Abstain from smoking  
● Smoking cessation for smokers  
● Healthy eating habit  
● Limit sodium intake  
● Weight management  
● Regular exercise | ● Monitor BMI  
● Monitor abdominal circumference  
● Diabetes | ● Measure blood pressure as above-mentioned | ● Blood pressure and lipid control  
● Beware of increased risk of hypotension in elderly  
● Monitor the adverse effect of drug treatment  
● Self-care  
● Carer education and support | ● Hypotension  
● Malignant hypertension  
● Target organ damage: nephropathy, neuropathy, cardiovascular complications | ● Optimise patient’s potential to cope with hypertension and its complications. Example: myocardial infarction, cerebrovascular disease, nephropathy, etc.  
● Provide support to carer and loved ones  
● Multidisciplinary approach in rehabilitation for stroke and renal failure |

### Reference:

1. Equipment for recording blood pressure

1.1 Sphygmomanometer
   i. Mercury sphygmomanometer – the most reliable type of instrument for recording blood pressure. However, mercury is being gradually phased out due to health and environmental hazard\(^1\). WHO recommends that mercury sphygmomanometers be retained for calibration purposes in designated laboratories\(^2\).
   ii. Electronic devices – can also be used, but periodic calibration should be done to ensure its accuracy.
   iii. Electronic devices that record the pressure in the fingers or the wrist should be avoided.

1.2 Checking of mercury sphygmomanometer
   i. The column of the manometer is in the intended position (vertical).
   ii. Mercury level is at zero when cuff is deflated.
   iii. No blockage of the air venting system at the top of the manometer
   iv. A sluggish response or bouncing of the mercury column during inflation and deflation usually indicates a blocked vent.
   v. No leakage from rubber tubing, hand pump and control valve:
      a. Roll a cloth cuff into its own tail.
      b. Pump up to 200 mmHg and wait for 10 seconds.
      c. Mercury should fall < 2 mmHg in 10 seconds.
      d. If fall > 2 mmHg, clamp circuit in sections to locate the leakage or replace the control valve.

1.3 Checking of electronic devices
   i. Routine checks - compare the reading with mercury sphygmomanometer.
   ii. Periodic calibration is needed.
   iii. If consistent discrepancies of more than 5 mmHg persist, refer to service manual or send the monitor to a trained technician for calibration.
2. Blood pressure recording techniques

i. The client should be advised to be seated for at least 5 minutes before the recording is taken.

ii. Arrange client in sitting position.

iii. Remove any constrictive clothing from the arm.

iv. Support client’s arm with the antecubital fossa at heart level.

v. Use an appropriate sized blood pressure cuff. The cuff should be wide enough to cover two thirds of the upper arm and its length should be long enough to encircle the whole arm.

vi. Advise client to relax and not to talk during blood pressure recording.

vii. Check blood pressure initially by palpation prior to auscultation.
   a. palpate the radial artery with your fingertips.
   b. inflate the cuff while simultaneously palpating the artery.
   c. note the point on the manometer at which the radial artery pulsation is no longer palpable. (This is the estimated systolic pressure.)
   d. deflate the cuff.

viii. Wait 30-60 seconds before reinflating.

ix. Place the stethoscope gently over the brachial artery and steadily inflate the cuff to the level of 30 mmHg above the estimated level of systolic pressure checked by palpation.

x. Deflate the blood pressure cuff by 2 mmHg per second.

xi. Record the first Korotkoff sound (the regular appearance of sound) as the systolic pressure.

xii. Record the last (5th) Korotkoff sound (the disappearance of sound) as the diastolic pressure. If sounds persist to zero, or close to zero, use the muffling sounds (4th Korotkoff sound) to indicate diastolic pressure.

xiii. Allow 1 minute between blood pressure recordings.

xiv. Before using an electronic device, check for pulse irregularity. If pulse irregularity is present, measure blood pressure manually using direct auscultation over the brachial artery.
3. **Precautions about blood pressure recording**

3.1 Recorder’s precautions

i. Read at eye level.

ii. Avoid digital preference. The blood pressure reading should be corrected to the nearest 2 mmHg.

iii. Choose the correct cuff size (see 2 v).

iv. Consistent use of the 4th or 5th Korotkoff sounds for recording (see 2 xii).

v. Correct arm positioning
   a. blood pressure changes 8-10 mmHg for every 10 cm that the antecubital fossa is above or below the heart level.
   b. arm well supported (diastolic pressure may be raised by as much as 10%).

vi. Deflate the cuff not too rapidly or too slowly (see 2 x).

vii. Avoid venous congestion due to repeated measurement.

viii. Adopt a unified standard in recording routinely to avoid variation among recorders.

3.2 Patient’s factors

i. Emotional factors including white coat hypertension: 24-hour ambulatory blood pressure monitoring and self BP monitoring at home can be used to address the white coat effect.

ii. Physical exertion: blood pressure will increase during exertion.

iii. After exercise, decrease in blood pressure may persist for more than one hour.

iv. After meals: blood pressure may decrease following meals; recording is not recommended within half an hour of eating.

v. Smoking and caffeine: should be avoided within 30 minutes prior to BP recording.

vi. Alcohol.

vii. Temperature extremes.

viii. Bladder and bowel distension.

ix. Pain.
4. **Home/ self BP monitoring**

4.1 Potential advantages and disadvantages of home monitoring

<table>
<thead>
<tr>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td> Providing information on response to antihypertensive medication</td>
<td></td>
</tr>
<tr>
<td> Improving patient adherence with therapy⁶</td>
<td></td>
</tr>
<tr>
<td> Evaluating</td>
<td> Reporting bias</td>
</tr>
<tr>
<td></td>
<td> Unsupervised alteration of medication</td>
</tr>
</tbody>
</table>

4.2 Self-measurement of BP

- Persons with an average BP 135/85 mmHg measured at home are generally considered to be hypertensive⁵.
- Two consecutive measurements are taken, at least 1 minute apart and with the person seated and blood pressure is recorded twice daily⁵.
- Initial assessment or the assessment of treatment effects should be for a 7-day period, with recordings performed in the morning and evening, and excluding values for the first 24 hours. The average of the readings is taken as the home BP level.
- Home measurement devices should be checked regularly.

**Reference:**


Module 2  Blood Pressure Measurement


Table 1. Identifiable causes of hypertension (the ABCDE mnemonic)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| **A** | Accuracy of diagnosis  
|   | obstructive sleep Apnea  
| **B** | renal artery Bruits (renovascular disease noise)  
|   | Bad kidneys (renal parenchymal disease)  
| **C** | excess Catecholamines  
|   | Coarctation of the aorta  
|   | Cushing's syndrome  
| **D** | Drugs (immunosuppressive agents, NSAID, COX-2 inhibitors, estrogens /  
|   | oral contraceptive, weight-loss agents, stimulants, mineralocorticoids,  
|   | antiparkinsonian, monoamine oxidase inhibitors, anabolic steroids,  
|   | sympathomimetics)  
|   | Diet (high salt intake, excessive alcohol intake, obesity)  
| **E** | excess Erythropoietin  
|   | Endocrine disorders (phaeochromocytoma, primary and secondary  
|   | hyperaldosteronism, hyper- or hypothyroidism, parathyroid disease,  
|   | Cushing syndrome)  

Table 2. Findings suggestive of secondary hypertension

<table>
<thead>
<tr>
<th>Findings</th>
<th>Disorder suspected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Snoring, daytime somnolence, obesity</td>
<td>Obstructive sleep apnea</td>
</tr>
<tr>
<td>Hypernatremia, hypokalemia, increased urinary excretion of potassium</td>
<td>Hyperaldosteronism</td>
</tr>
<tr>
<td>Renal artery bruits, renal insufficiency, atherosclerotic cardiovascular disease, oedema, elevated blood urea nitrogen and creatinine levels, proteinuria</td>
<td>Renal parenchymal disease</td>
</tr>
<tr>
<td>Systolic/diastolic abdominal bruit</td>
<td>Renovascular disease</td>
</tr>
<tr>
<td>Use of sympathomimetics, perioperative setting, acute stress, tachycardia</td>
<td>Excess catecholamines</td>
</tr>
<tr>
<td>Decreased or delayed femoral pulses, abnormal chest radiograph</td>
<td>Coarctation of aorta</td>
</tr>
</tbody>
</table>
## Findings

<table>
<thead>
<tr>
<th>Findings</th>
<th>Disorder suspected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight gain, fatigue, weakness, hirsutism, amenorrhea, moon facies, dorsal hump, purple striae, truncal obesity, hypokalemia</td>
<td>Cushing's syndrome</td>
</tr>
<tr>
<td>Use of drug (immunosuppressive agents, NSAID, COX-2 inhibitors, estrogens / oral contraceptive, weight-loss agents, stimulants, mineralocorticoids, antiparkinsonian, monoamine oxidase inhibitors, anabolic steroids, sympathomimetics)</td>
<td>Side effects of drugs</td>
</tr>
<tr>
<td>High salt intake, excessive alcohol intake, obesity</td>
<td>Unhealthy diet</td>
</tr>
<tr>
<td>Erythropoietin use in renal disease, polycythemia in chronic obstructive pulmonary disease (COPD)</td>
<td>Erythropoietin side effect</td>
</tr>
<tr>
<td>Paroxysmal hypertension, headaches, diaphoresis, palpitations, tachycardia</td>
<td>Phaeochromocytoma</td>
</tr>
<tr>
<td>Fatigue, weight gain, hair loss, diastolic hypertension, muscle weakness</td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Heat intolerance, weight loss, palpitation, systolic hypertension, exophthalmos, tremor, tachycardia</td>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Kidney stones, osteoporosis, depression, lethargy, muscle weakness</td>
<td>Hyperparathyroidism</td>
</tr>
<tr>
<td>Headaches, fatigue, visual problems, enlargement of hands, feet, tongue</td>
<td>Acromegaly</td>
</tr>
</tbody>
</table>

### Reference:


The aims of the evaluation are:

• to assess lifestyle and identify cardiovascular risk factors that may affect prognosis and guide treatment,

• to reveal identifiable causes of high blood pressure, and

• to assess the presence or absence of target organ damage and cardiovascular disease. (Box 1)

Box 1 Target organ damage

- Heart: Left ventricular hypertrophy (ECG / Echocardiogram)
- Renal: Albuminuria and / or elevation of plasma creatinine (>110 µmol/L)
- Vessel: USG or radiological evidence of atherosclerotic plaque (carotid, iliac, femoral or aorta), generalised or focal narrowing of the retinal arteries
  - Angina or prior myocardial infarction
  - Prior coronary revascularisation
  - Heart failure
- Brain:
  - Stroke or transient ischaemic attack
  - Dementia
- Chronic renal disease
- Peripheral arterial disease
- Retinopathy: Hemorrhages or exudates, Papilloedema
The aims of the evaluation are:
• to assess lifestyle and identify cardiovascular risk factors that may affect prognosis and guide treatment,
• to reveal identifiable causes of high blood pressure, and
• to assess the presence or absence of target organ damage and cardiovascular disease.

### History
- Symptoms suggestive of secondary causes
- Symptoms (present or past history) of cardiovascular risk factors: age>55 for men and age>65 for women/ smoking/ raised total cholesterol/ diabetes mellitus/ family history of premature cardiovascular disease (men under age 55 or women under age 65)
- Target organ damage: retinopathy/ left ventricular hypertrophy/ heart failure/ coronary heart disease (CHD)/ proteinuria or renal disease like renal failure / peripheral vascular disease (PVD)/ cerebrovascular accident (CVA)
- Factors that affect choice of drug treatment like gout, bronchospasm.
- Assessment of lifestyle: exercise, diet, alcohol
- Drug history
- Psychosocial factors
- Family history: hypertension (HT), diabetes, stroke, renal disease, myocardial infarction and other cardiovascular system (CVS) risk factors

### Physical examination
- Body weight, height, Body Mass Index
- Features of Cushing’s syndrome / Acromegaly (endocrine case of HT)
- Skin stigmata of neurofibromatosis (phaeochromocytoma)
- Radial/brachial femoral delay, precordial or chest murmurs (aortic coarctation or aortic disease)
- Abdominal examination: enlarged kidney, abdominal bruit
- Signs of organ damage: peripheral arterial disease, fundi abnormalities, carotid bruit, neurological defects, CVS examination
**Routine laboratory investigation**

<table>
<thead>
<tr>
<th><strong>Recommended Tests</strong></th>
<th><strong>Justification</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General</strong></td>
<td></td>
</tr>
<tr>
<td>Urine analysis</td>
<td>• Detection of hypertensive nephropathy</td>
</tr>
<tr>
<td></td>
<td>• Look for red blood cells, casts, glucose and protein</td>
</tr>
<tr>
<td>Fasting glucose level</td>
<td>• Detection of concomitant impaired glucose tolerance and diabetes</td>
</tr>
<tr>
<td><strong>Renal function test</strong></td>
<td></td>
</tr>
<tr>
<td>Sodium, Potassium, Urea, Creatinine</td>
<td>• Baseline level of electrolytes to aid adjustment of future pharmacotherapy (e.g. thiazide, beta-blockers, Angiotensin-converting enzyme inhibitors)</td>
</tr>
<tr>
<td></td>
<td>• Detection of hypertensive nephropathy</td>
</tr>
<tr>
<td></td>
<td>• Detection of electrolytes disturbance associated with endocrine disorders</td>
</tr>
<tr>
<td><strong>Lipid profile</strong></td>
<td></td>
</tr>
<tr>
<td>Total Cholesterol</td>
<td>• Detection of concomitant cardiovascular risk factors</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>• Guidance for antihypertensive and lipid-lowering pharmacotherapy</td>
</tr>
<tr>
<td>HDL-Cholesterol</td>
<td></td>
</tr>
<tr>
<td>LDL-Cholesterol</td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td></td>
</tr>
<tr>
<td>12-lead electrocardiogram</td>
<td>• Detection of cardiac complication as possible end-organ damage (left ventricular hypertrophy; cardiac ischemia)</td>
</tr>
</tbody>
</table>
Reference:


Module 5  Dietary Intervention

The Dietary Advice to Stop Hypertension eating plan

The Dietary Advice to Stop Hypertension (DASH) eating plan, developed by United States National Institute of Health, features plenty of fruits, vegetables, whole grains, and other foods that are heart healthy and lower in salt/sodium. It is recommended for people with high blood pressure. Please refer to Table 1 for DASH eating plan.

The DASH eating plan has the following characteristics:
1. Rich in fruits, vegetables
2. Rich in potassium, magnesium and calcium
3. Low in cholesterol, saturated and total fat
4. Low in sodium
5. Low in sweets and added sugars

Table 1. The DASH eating plan shown below is based on 2000 calories a day. The number of daily servings in a food group one requires may vary from those listed, depending on the caloric needs.

<table>
<thead>
<tr>
<th>Food Group</th>
<th>Daily Servings</th>
<th>Examples of Serving Sizes</th>
</tr>
</thead>
</table>
| Grain and grain products          | 6-8            | 1 slice bread
1 cup ready-to-eat cereal
1/2 cup cooked rice, pasta, or cereal |
| Vegetables                        | 4-5            | 1 cup raw leafy vegetables
1/2 cup cooked vegetables
1/2 cup vegetable juice |
| Fruits                            | 4-5            | 1 medium fruit
1/4 cup dried fruit
1/2 cup fresh, frozen, or canned fruit
1/2 cup fruit juice |
| Low fat or fat free dairy products| 2-3            | 1 cup milk
1 cup yoghurt
1 1/2 ounce cheese |
<p>| Lean meats, poultry, and fish     | 6 or less      | 1 ounce (28 grams) cooked lean meat, skinless poultry, or fish |</p>
<table>
<thead>
<tr>
<th>Food Group</th>
<th>Daily Servings</th>
<th>Examples of Serving Sizes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuts, seeds, and dry beans</td>
<td>4-5 per week</td>
<td>1/3 cup or 1 1/2 ounces nuts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 tablespoon or 1/2 ounces seeds</td>
</tr>
<tr>
<td>Fats and oils</td>
<td>2-3</td>
<td>1 teaspoon soft margarine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 tablespoon low-fat mayonnaise</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 tablespoons light salad dressing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 teaspoon vegetable oil</td>
</tr>
<tr>
<td>Sweets</td>
<td>5 or less per week</td>
<td>1 tablespoon sugar</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 tablespoon jelly or jam</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 cup lemonade</td>
</tr>
</tbody>
</table>

Note: Volume of cup = 240 ml

**Specific instructions on dietary intervention** (adapted from DASH eating plan)

**Salt**

Restrict salt intake to less than 5 grams of table salt per day (around 1 teaspoon), as sodium is a main dietary factor for elevated blood pressure. The 5 grams includes all salt and sodium consumed, including that used in cooking and at the table. Please refer to table 2 for practical advice.

**Tips to reduce salt and sodium**

- Compare nutrition labels and choose prepackaged foods that are lower in sodium.
- Use fresh poultry, fish, lean meat and vegetables. Limit consumption of foods that are high in salt content such as sauces, preserved meat and vegetables, and canned and processed foods like luncheon meat and sausages.
- Cut down on convenient and instant foods, canned soups or broths as they often contain a lot of sodium.
- Cook food with less salt. Use spices instead of salt in cooking and at the table. Limit condiments, such as mustard, ketchup, pickles and soy sauce.
- Use more natural low-sodium seasoning, such as ginger, green onions, garlic, pepper powder, lemon juice, etc. to replace salt or soy sauce in cooking.
Salt substitutes

- A potassium-rich diet may help to reduce blood pressure.
- Potassium should be from food sources, not from supplements.
- Many fruits and vegetables e.g. potato, spinach, tomato, lettuce, banana, orange, apple and some dairy products e.g. yoghurt, and fish are rich sources of potassium.
- However, potassium-rich diet should be avoided in patients with chronic renal failure or taking potassium-sparing diuretics.

Table 2. Practical advice for low salt diet

<table>
<thead>
<tr>
<th>Meals and foods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breakfast</strong></td>
</tr>
<tr>
<td>• 1 cup oatmeal</td>
</tr>
<tr>
<td>• 2 slice whole wheat bread</td>
</tr>
<tr>
<td>• 2 teaspoons of soft margarine</td>
</tr>
<tr>
<td>• 1 cup low fat or skimmed milk</td>
</tr>
<tr>
<td>• 1 medium fruit</td>
</tr>
<tr>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td>• 2 cups cooked rice or pasta</td>
</tr>
<tr>
<td>• 3 ounces (84 grams) of cooked meat, fish or poultry</td>
</tr>
<tr>
<td>• 1/8 teaspoon of salt in cooking, or equivalent</td>
</tr>
<tr>
<td>• 1 teaspoon vegetable oil</td>
</tr>
<tr>
<td>• 1 cup cooked vegetable</td>
</tr>
<tr>
<td>• 1 medium fruit</td>
</tr>
<tr>
<td><strong>Dinner</strong></td>
</tr>
<tr>
<td>• 1 medium baked potato</td>
</tr>
<tr>
<td>• 1 teaspoon of sour cream</td>
</tr>
<tr>
<td>• 3 ounces (84 grams) of cooked meat, fish or poultry</td>
</tr>
<tr>
<td>• 1/8 teaspoon of salt in cooking, or equivalent</td>
</tr>
<tr>
<td>• 1 teaspoon vegetable oil</td>
</tr>
<tr>
<td>• 1 cup cooked vegetable</td>
</tr>
<tr>
<td>• 1 medium fruit</td>
</tr>
</tbody>
</table>
Meals and foods

Snack
- 1 medium fruit
- 1 slice whole wheat bread
- 1.5 ounces reduced fat cheddar cheese, low sodium
- 1 cup low fat yoghurt

Total salt used per day: 1/4 teaspoon of salt

Note: Salt exchange list:
- 1/8 teaspoon of salt = 1/2 teaspoon of soya sauce
- = 1 oyster sauce
- = 1 tablespoon of Ketchup

Carbohydrate intake
- Carbohydrate should provide half of the total energy intake.
- Meals should contain mostly complex carbohydrates with an emphasis on high-fibre foods such as vegetables, whole grain cereals and fruits.
- Simple sugar including sugar sweetened beverages (e.g. soft drinks, fruit juice) and snacks with high sugar content (e.g. cakes) should provide no more than 10% of total energy intake.

Fruit and Vegetables
- Include 4-5 servings of fruit a day.
- Eat at least 4-5 servings of vegetables a day.
- Choose fruit more often than juice.
- Choose a wide variety of fruit and vegetables.

Protein
- Protein should provide 15-20% of total energy intake.
- Good sources of protein are fish, seafood, lean meat, chicken, low fat dairy products, nuts and soy bean products which have not been deep-fried.
Module 5      Dietary Intervention

Fat²
• No more than 30% of total energy intake should come from fat.
• Cut down on foods with high saturated fat.
  ➢ High-fat meat and meat products, such as bacon, spare ribs, sausages, and canned meat like luncheon meat.
  ➢ High-fat poultry parts, such as chicken skin and chicken wings.
  ➢ High-fat dairy products, such as ice-cream, whole milk and cheese made from whole milk.
  ➢ Fat and oil, such as butter, cream, lard and chicken fat.
  ➢ High-fat foods from plants: Palm oil, coconut, and coconut products, such as coconut oil and coconut milk.
• Cut Down on Foods High in Cholesterol. Foods high in cholesterol include:
  ➢ Offal, such as brain, liver and kidney.
  ➢ Seafood, such as octopus, squid, fish head, and roe of shrimp and crab.
  ➢ Egg yolk is high in cholesterol but also rich in nutrients and can be part of a healthy diet. If a person has an egg for breakfast, he/she might want to substitute some vegetarian choices for their other meals of the day.
• Cut Down on Foods that Contain Trans Fat. Foods high in Trans Fat: Hard margarine, cookies, cakes, croissants, French fries, potato chips and doughnuts.
• Use vegetable oil such as canola oil and peanut oil for cooking instead of animal fat.

Alcohol Consumption
• Consumption should be limited to less than 2 standard drinks for men and less than 1 standard drink for women every day.
• Each standard drink contains 10 grams of pure alcohol. Defining one standard drink as 10 grams of pure alcohol, it equates to about 250 ml of regular beer at 5% of alcohol content, one small glass (100 ml) of wine at 12% alcohol content, or one pub measure (30ml) of hard liquor at 40% of alcohol content.

For more information on alcohol screening and brief intervention, please visit the following web page from the Department of Health https://www.change4health.gov.hk/en/alcoholfails/
Reference:


1. Effect of Exercise

Epidemiological studies suggest that regular physical activity may be beneficial for both prevention and treatment of hypertension, to enable weight loss, for functional health status, and to diminish all-cause mortality and risk of cardiovascular disease. Cross-sectional studies of select populations from China and other Eastern populations have confirmed the presence of a strong association between physical inactivity and an adverse heart disease risk factor profile. In Japanese men, duration of walk-to-work and leisure-time physical activity was significantly associated with a reduction in the risk for incident hypertension. A meta-analysis of randomized controlled trials concluded that dynamic aerobic endurance training reduces resting systolic and diastolic blood pressures by 3.0/2.4 mmHg, and daytime ambulatory blood pressure by 3.3/3.5 mmHg. The reduction in resting blood pressure was more pronounced in the hypertensive group (-6.9/ -4.9 mmHg) than in the normotensive group (-1.9/-1.6 mmHg). Even moderate levels of exercise lowered blood pressure, and this type of exercise also reduced body weight, body fat and waist circumference. Dynamic resistance exercise can also decrease resting blood pressure by 3.5/3.2 mmHg.

2. Recommendations for Exercise Prescription

The following table summarises the exercise prescription that is recommended for patients with hypertension in general.

Regular physical activity of even lower intensity and duration, however, has been shown to be associated with about a 20% decrease in mortality in cohort studies. Individuals engaging in resistance exercise should seek guidance by a trained professional, for appropriate machine adjustment, selection of specific exercises, appropriate initial exercise prescription, and subsequent exercise progression. Resistive isotonic activities, when done as the only form of exercise training, are not recommended for lowering blood pressure in hypertensive patients. An exercise prescription for achieving and maintaining flexibility, such as proper stretching for all the major joints, may be advised after a thorough warm-up and during the cool-down period.
Physical Activity Profile

<table>
<thead>
<tr>
<th>Recommendations*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Frequency</strong></td>
</tr>
<tr>
<td>• Perform aerobic exercise preferably all days of the week.</td>
</tr>
<tr>
<td>• Supplemented by resistance exercise twice to thrice weekly on nonconsecutive days.</td>
</tr>
<tr>
<td><strong>Intensity</strong></td>
</tr>
<tr>
<td>• Aerobic exercise should be at least at moderate intensity (e.g. brisk walking), corresponding approximately to 40-60% of maximal aerobic capacity (VO2max). Relatively, moderate-intensity activity could be expressed as a level of effort of 5 or 6 on a scale of 0 to 10 (where 0 is the level of effort of sitting, and 10 is maximal effort) or 50–70% of maximum heart rate.</td>
</tr>
<tr>
<td>• Resistance exercise should be at moderate intensity, which could be expressed as 50-70% of 1-repetition maximum (1-RM– maximum amount of weight one can lift in a single repetition for a given exercise).</td>
</tr>
<tr>
<td><strong>Time</strong></td>
</tr>
<tr>
<td>• Perform 30 to 60 mins per day of aerobic exercise continuously or intermittently in bouts of at least 10 mins accumulated to total of at least 30 mins per day.</td>
</tr>
<tr>
<td>• Each session of resistance exercise should minimally include 8–10 exercises and should consist of at least 1 set of 8–12 repetitions per exercise.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>• Emphasis on aerobic exercises such as walking, jogging, cycling and swimming. Rope skipping is also a very good option that can be performed every day, requires little equipment and learning, and involves a lot of muscle group. However, any activity that uses large muscle groups, can be maintained continuously, and is rhytmical and aerobic in nature is recommended as the primary modality for those with hypertension.</td>
</tr>
<tr>
<td>• Resistance exercise should involve the major muscle groups (legs, hips, chest, back, abdomen, shoulders, and arms). Either machine weights or free weights might be used while the former is likely the safest approach. Resistance exercise performed should be alternating between upper- body and lower-body works to allow for adequate rest between exercises. Some examples of resistance exercise include chest press, shoulder press, triceps extension, biceps curl, pull-down (upper back), lower-back extension, abdominal crunch/curl-up, quadriceps extension or leg press, leg curls (hamstrings), and calf raise.</td>
</tr>
</tbody>
</table>

* Given that many patients may present with comorbidities, it may be necessary to tailor the exercise prescription accordingly.
3. Rate of Progression

In November 2010, the American College of Sports Medicine and the American Diabetes Association published a joint position statement on exercise recommendations for patients with Type 2 diabetes mellitus which covers rate of progression. Their general principles, as outlined below, can also be applied to patients with hypertension:

- To avoid injury, progression of frequency and intensity of resistance exercise should occur slowly.
- Gradual progression of intensity of aerobic exercise is also advisable to enhance compliance.

4. Evaluation of patient with hypertension before recommending an exercise programme

The need for and scope of pre-exercise evaluation of the cardiovascular status will depend on the extent of the envisaged exercise and on the patient’s symptoms and signs, total cardiovascular risk and associated clinical conditions. The risk of cardiovascular disease in patients with hypertension is determined not only by the level of blood pressure, but also by the presence or absence of target organ damage and other risk factors such as smoking, dyslipidaemia and diabetes, as shown in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. These factors independently modify the risk for subsequent cardiovascular disease, and their presence or absence is determined during the routine evaluation of patients with hypertension (i.e., history, physical examination, and/or laboratory tests). High-intensity resistance training should not be initiated for persons without prior exposure to more moderate resistance exercise independently of age, health status, or fitness level. Therefore, patients with hypertension should consult a primary care practitioner prior to any substantive increase in physical activity, particularly vigorous-intensity activity.
5. Special Precautions

1. Intensive isometric exercise such as heavy weight lifting can have a marked pressor effect and should be avoided.

2. If hypertension is poorly controlled, heavy physical exercise as well as maximal exercise testing should be discouraged or postponed until appropriate drug treatment has been instituted and blood pressure lowered. When exercising, it appears prudent to maintain systolic blood pressures at ≤220 mmHg and/or diastolic blood pressures ≤105 mmHg.

3. β-blockers and diuretics may adversely affect thermoregulatory function and cause hypoglycaemia in some individuals. In these situations, educate patients about the sign and symptoms of heat intolerance and hypoglycaemia, and the precautions that should be taken to avoid these situations.

4. Antihypertensive medications such as calcium channel blockers, α-blockers and vasodilators may lead to sudden reductions in post-exercise blood pressure. Extend and monitor the cool-down period carefully in these situations.

5. β-blockers, particularly the non-selective types, may reduce sub-maximal and maximal exercise capacity primarily in patients without myocardial ischaemia. Consider using perceived exertion to monitor exercise intensity in these individuals.

6. Patients should be informed about the nature of cardiac prodromal symptoms e.g. shortness of breath, dizziness, chest discomfort or palpitation and seek prompt medical care if such symptoms develop.
Module 6  Exercise Recommendations to People with Hypertension (Adopted from Department of Health Central Health Education Unit Exercise Prescription 2012 Edition)

Reference:
Module 7  Drug Treatment for People with Hypertension

Treatment algorithm

Drug treatment for essential HT

Compelling indication / contraindication over choice of drug

Yes

Go to Appendix 1

No

Start with either ACEI (or ARB if ACEI intolerant), calcium channel blocker or thiazide-type diuretic

- No response or not tolerated, switch to another drug
- Inadequate response but tolerated, add a second drug from different class

If blood pressure goal is still not reached, increase dose or consider adding third drug from different class

Refer to specialist if blood pressure still not under control

Choices of antihypertensive drugs and goals of therapy

The ultimate goal of anti-hypertensive therapy is to reduce cardiovascular morbidity and mortality. There are excellent clinical outcome trial data proving that lowering blood pressure with different classes of anti-hypertensives, including angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (BBs), calcium channel blockers (CCBs), and thiazide-type diuretics, will all reduce the complications of hypertension.\(^4,6-11,14\) It should be emphasized that the perceived risk reduction was directly proportional to blood pressure reduction rather than the drug class used to achieve it,\(^1\) although different drug classes were recognized to have unique benefits specific to individual patient populations.\(^28\)
It has also shown that the lower the blood pressure the better, and that this should be the primary objective of any treatment strategy. Therefore it is important to treat in order to reach the target blood pressure levels whichever drug(s) is/are used, i.e. for uncomplicated hypertensive patients, treating SBP and DBP to targets <140/90mmHg, or to 130/80mmHg or lower if tolerable. In patients with co-morbidities of diabetes or renal disease, the blood pressure target is <130/80mmHg. While for patients with coronary artery disease, the blood pressure should be lowered slowly, and caution is advised in inducing falls of diastolic blood pressure below 60 mmHg if the patient also has diabetes mellitus or is over the age of 60 years.

Within the array of available agents, the choice of drugs will be influenced by many factors, including:

1. The previous, favourable or unfavourable, experience of the individual patient with a given class of drugs.
2. The cost of drugs, either to the individual patient or to the health care provider, although cost considerations should not predominate over efficacy and tolerability in any individual patient.
3. The presence of target organ damage, renal disease, diabetes or the presence of other coexisting cardiovascular disease that may either favour or limit the use of particular classes of antihypertensive drugs. Approach to patients with compelling indications is described in Appendix 1.
4. A significant number of patients require two or more anti-hypertensive drugs in order to achieve blood pressure control. The possibility of interactions with drugs used for other conditions present in the patient.
5. There is substantial inter-individual variation in response to single drugs with large absolute falls in some patients, contrasting with little or no response in others.

The family doctor should tailor the choice of drugs to the individual patient, after taking all these factors into account.
With reference to the UK and US guidelines, the rationales on selecting different classes of drugs for uncomplicated hypertensive patients are introduced below.

**Thiazide-type diuretics**
Thiazide-type diuretics have been widely studied and shown to be the drug most likely to confer benefit as first-line treatment for most patients. In these trials, including ALLHAT thiazide-type diuretics had significantly prevented the cardiovascular complications of hypertension. Thiazide-type diuretics are generally well tolerated and have good blood pressure lowering effect in particular older patients. Thiazide-type diuretics are also more affordable than other antihypertensive agents and are recommended as the initial therapy for most patients with hypertension by US guideline.

**Angiotensin-converting enzyme inhibitors (ACEI)/ Angiotensin II Receptor Antagonists (ARB)**
It was demonstrated that younger patients and Caucasians tend to have higher serum renin levels than those older patients and the black population, and thus should have better response to ACEI/ARB which inhibit the renin-angiotensin system. ACEI/ARB is recommended by the UK guideline as the initial drug choice for people aged <55. Apart from younger patients, ACEI/ARB are also the drug of choice for patients with heart failure, left ventricular dysfunction, myocardial infarction, ischemic heart disease, diabetic nephropathy, microalbuminuria or history of stroke.

**Calcium Channel Blockers (CCB)**
Data showed that the blood-pressure lowering effect of CCB is good in most patients. It is well tolerated in general. Clinical trial data also proved that lowering BP with CCB reduces the complications of hypertension. It is the most commonly used anti-hypertensive medication by private doctors in Hong Kong.
**Beta-blocker**

The decision not to recommend Beta-blockers for first line therapy is based on evidence from head-to-head trials\textsuperscript{19,20,21,22} that beta-blockers were less effective than the comparator drug at reducing major cardiovascular events, in particular stroke. An additional concern is the increased risk of developing diabetes, particular with the combination of thiazide-type diuretic. However, beta-blockers may be considered in younger people, particularly\textsuperscript{24}:

- for those with an intolerance or contraindication to ACE inhibitors and angiotensin-II antagonists or
- for women of child-bearing potential or
- for patients who have previously had a heart attack, angina, heart failure or an irregular heart beat
## Appendix 1

### Compelling and Possible Indications and Contraindications for the Major Classes of Antihypertensive Drugs

<table>
<thead>
<tr>
<th>Class of Drug</th>
<th>Compelling Indications</th>
<th>Possible Indications</th>
<th>Compelling Contraindications</th>
<th>Possible Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE Inhibitors (ACEI)</td>
<td>Heart failure, Left ventricular dysfunction, Post myocardial infarction, Diabetic nephropathy</td>
<td>Proteinuric renal disease</td>
<td>Pregnancy, Bilateral renal artery stenosis, Hyperkalaemia</td>
<td>Renal impairment</td>
</tr>
<tr>
<td>Angiotensin II Receptor Blockers (ARB)</td>
<td>ACE inhibitor intolerance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha-Blockers</td>
<td>Benign prostatic hypertrophy</td>
<td></td>
<td></td>
<td>Orthostatic hypotension</td>
</tr>
<tr>
<td>Beta-Blockers</td>
<td>Angina, Post myocardial infarction Tachyarrhythmias</td>
<td>Heart failure (low dose)</td>
<td>Asthma, chronic obstructive pulmonary disease, Heart block</td>
<td>Peripheral vascular disease</td>
</tr>
<tr>
<td>Calcium Channel Blockers (dihydropyridine)</td>
<td>Elderly patients, Isolated systolic hypertension</td>
<td>Angina, Peripheral vascular disease</td>
<td>Congestive heart failure</td>
<td></td>
</tr>
<tr>
<td>Calcium Channel Blockers (rate limiting, e.g. verapamil, diltiazem)</td>
<td>Angina</td>
<td>Heart block</td>
<td>Congestive heart failure, combination with beta-blockers</td>
<td></td>
</tr>
<tr>
<td>Thiazide/ thiazide-like Diuretics</td>
<td>Heart failure, Elderly patients, Isolated systolic hypertension</td>
<td>Gout</td>
<td>Dyslipidaemia, Pregnancy, Sexually active males</td>
<td></td>
</tr>
</tbody>
</table>
Reference:


The aims of the annual assessment are:
1. to detect cardiovascular, cerebrovascular and renal complications
2. to assess patient’s knowledge, attitude and compliance in respect of living with hypertension and drug treatment
3. to give appropriate advice to patient on healthy lifestyle and cardiovascular related risk factors
4. to ensure satisfactory control over the year (average of most recent three readings of <140/90 mmHg)

History:
1. New symptoms of cardiovascular complications like angina, neurological symptoms
2. Checking smoking status
3. Alcohol intake
4. Exercise
5. Family history of premature coronary heart disease
6. Assessing patient’s ideas and concerns about hypertension, side effects of drugs, compliance to treatment and effect on quality of life

Physical examination\(^1,2,3\):
1. Measure blood pressure with a mercury sphygmomanometer or validated electronic device
2. Check body mass index
3. Cardiovascular examination including peripheral pulses, bruits
**Laboratory Investigation**:  

<table>
<thead>
<tr>
<th><strong>Recommended Tests</strong></th>
<th><strong>Justifications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Fasting blood glucose | Detection of concomitant diabetes  
                       | Guidance for cardiovascular risk factor control  |
| Urine for protein/ albumin | Detection of hypertensive nephropathy  |
| Uric acid if patient is on diuretic | Detection of diuretic-induced hyperuricaemia  |
| Optional - Random spot urine albumin: creatinine ratio (ACR) | Detection of hypertensive nephropathy  |
| **Renal function test** |                    |
| Sodium, Potassium, Urea, Creatinine | Detection of hypertensive nephropathy  
                       | Detection of diuretic-induced electrolyte disturbance  |
| **Lipid profiles**    |                    |
| Total Cholesterol     | Detection of concomitant cardiovascular risk factors  |
| Triglyceride          | Guidance for antihypertensive and lipid-lowering pharmacotherapy  |
| HDL-Cholesterol       |                    |
| LDL-Cholesterol       |                    |

**Management:**  
1. Review the risk factors and blood results  
2. Assess the side effects of drug treatment and manage accordingly  
3. Inform and encourage patient on lifestyle modifications like salt reduction and exercise  
4. Explore reasons for non-compliance  
5. Ensure patient understands nature of hypertension and benefits of long-term therapy and follow-up
Reference:


Module 9  Lipid Management in Hypertensive Patients

Aims of this module

To provide recommendations on lipid management in adult hypertensive patients for primary prevention of cardiovascular disease (CVD) in primary care setting.\(^\text{Note}\).

Screening

Screening of lipid profile should be performed for all newly diagnosed hypertensive patients, and as a part of the annual assessment\(^1\). This information, together with information on other risk factors, is useful in determining the individual’s cardiovascular risk and provides insight into the subsequent management.

Global risk assessment

In addition to hypertension and dyslipidaemia, there are other major cardiovascular risk factors, such as advancing age, male gender, cigarette smoking, obesity, physical inactivity, and family history of premature cardiovascular disease\(^2\). The total risk of developing CVD is determined by the combined effect of cardiovascular risk factors, which commonly coexist and act multiplicatively. An individual with several mildly raised risk factors may be at a higher total risk of CVD than someone with just one elevated risk factor\(^3\). Therefore, the global risk approach should be considered in every cardiovascular risk assessment including patients with hypertension. For all identified modifiable cardiovascular risk factors, they should be managed as possible. Periodic review of the cardiovascular risk is also necessary.

\(^\text{Note}\) For lipid management in diabetic patients, please refer to Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care Settings.
Cardiovascular risk assessment Tools

**Background**
Cardiovascular risk assessment tools aim at helping physicians to estimate the risk of cardiovascular events for individuals without known cardiovascular diseases, based on the presence of different risk factors. The predicted risk of an individual can be a useful guide for making clinical decisions on the intensity of interventions, which should always be individualised. These multivariate cardiovascular risk assessment tools can usually be interpreted easily by referring simplified charts or tables, or by web-based calculators, and most of them can be accessed easily on the internet. There is currently no tool specifically designed for Chinese populations.

It has to emphasise that estimation of the cardiovascular risk is not necessary for individuals with known very high or high risk conditions (Table 1). Lipid lowering therapy should be considered for these individual unless contraindicated.

<table>
<thead>
<tr>
<th>Risk level</th>
<th>Clinical presentation of individuals</th>
</tr>
</thead>
</table>
| Very high risk | (1) Individuals with established coronary artery disease, atherosclerotic cerebrovascular disease, aortic aneurysm or peripheral artery disease  
(2) Individuals with diabetes mellitus with chronic kidney disease  
(3) Individuals with familial hypercholesterolemia |
| High risk | (1) Individuals with moderate to severe chronic kidney disease (estimated glomerular filtration rate [eGFR] <60ml/min/1.73 m²)  
(2) Individuals with diabetes mellitus without established coronary artery disease, atherosclerotic cerebrovascular disease, aortic aneurysm, peripheral artery disease or chronic kidney disease |
Examples of cardiovascular risk assessment tools (Table 2)

1. **Framingham-based**
   - The original Framingham risk score (published in 1998) derived from Framingham Heart Study, a prospective cohort of largely Caucasian population, were widely adapted worldwide, such as in National Cholesterol Education Program (NCEP), Joint British Societies 2 (JBS2) and the New Zealand Cardiovascular Risk Charts; the former two guidelines had been widely used as reference in the public sectors in Hong Kong (information as at Feb 2017)
   - The Framingham system had been recalibrated for Asian populations for different cohorts, for example,
     - Singapore-adapted Framingham Risk Score: adjusted for Chinese, Malay and Indian populations in Singapore
     - Asia Pacific Cohort Studies Collaboration: cohorts from Japan, Korea, Singapore and China
     - The Chinese Multi-Provincial Cohort Study: Chinese cohorts from mainland China
   - It had been suggested that Framingham equation can be applied to the Hong Kong Chinese population but requires recalibration in men due to overestimation of the risk. There is currently no recalibrated tool available for local use

2. **Systemic Coronary Risk Evaluation (SCORE)**
   - Based on European cohorts
   - Recommended by European Society of Cardiology/ European Atherosclerosis Society (ESC/EAS)

3. **QRISK**
   - Based on patient data from England and Wales in the United Kingdom
   - Included more medical variables such as type 2 diabetes, chronic renal disease, atrial fibrillation, and rheumatoid arthritis
   - Recommended by the National Institute of Clinical Excellence (NICE)

4. **Pooled Cohort Studies Equations**
   - Derived from Whites and African Americans cohorts
   - Recommended by American College of Cardiology/ American Heart Association (ACC/AHA)
   - Study had questioned its validity in Hong Kong Chinese due to poor discrimination power and calibration when applied to the Chinese population in Hong Kong
Table 1. Examples of the cardiovascular risk assessment tools (information as at Feb 2017)

<table>
<thead>
<tr>
<th>Risk estimation system</th>
<th>Recommending guideline</th>
<th>Variables</th>
<th>Endpoint</th>
<th>Remarks</th>
</tr>
</thead>
</table>
| Framingham-based       | • NCEP guidelines\(^6\)  
                         • JBS2 guidelines\(^7\)  
                         • New Zealand guidelines\(^8\)  
                         • Singapore guideline\(^9\) | Sex, age, total cholesterol, HDL-C, SBP, smoking status, DM, HT treatment | 10-year risk of CAD events (in original version) | NCEP and JBS2 guidelines are commonly used as reference in public sectors |
| SCORE\(^13\)           | • ESC/EAS Guidelines for the management of dyslipidaemias\(^14\)  
                         • European Guidelines on cardiovascular disease prevention in clinical practice\(^15\) | Sex, age, total cholesterol or total cholesterol/HDL-C ratio, SBP, smoking status | 10-year risk of CVD mortality |  |
| QRISK2\(^16\)          | • NICE guidelines on lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease\(^17\) | Sex, age, race, total cholesterol/HDL-C ratio, SBP, smoking status, DM, HT treatment, family history, BMI, chronic disease | 10-year risk of CVD events |  |
| Pooled Cohort Studies Equations\(^18\) | • ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk\(^19\) | Sex, age, race (white or other/African American), total cholesterol, HDL-C, SBP, smoking status, DM, HT treatment | 10-year risk for the first atherosclerotic CVD event | Poor Calibration for Hong Kong Chinese\(^12\) |

Abbreviations:  
BMI: Body mass index  
CVD: Cardiovascular disease  
DM: Diabetes mellitus  
HT: Hypertension  
LDL-C: Low-density lipoprotein cholesterol  
CAD: Coronary artery disease  
HDL-C: High-density lipoprotein cholesterol  
SBP: Systolic blood pressure
**Treatment targets**

The treatment target should be individualised for different patients. In general, the higher the cardiovascular risk, the more worthwhile to start lipid lowering therapy. For patients who have very high risk or high risk conditions (*Table 1*), lipid lowering therapy should be considered unless contraindicated. Many of the guidelines recommend different treatment goals for patients who have been stratified under different risk categories. There are also guidelines recommending the use of lipid lowering drugs for patients considered as high risk and do not recommend specific treatment targets. The treatment targets (if available) for primary prevention of some of the international guidelines are listed for reference in *table 2*.

For lipid management in diabetic patients, please refer to Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care Settings.
Table 2. Treatment target levels of lipid (if available) for primary prevention in some of the international guidelines (information as at Feb 2017)

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Risk Category</th>
<th>Lipid Target (if any)/ treatment strategies</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCEP (2004)</td>
<td>Low: 0-1 risk factor</td>
<td>LDL-C &lt; 4.1mmol/L</td>
<td>Lipid targets are commonly used as reference in public sectors</td>
</tr>
<tr>
<td></td>
<td>Moderate: ≥ 2 risk factors and 10-year CHD risk &lt; 10%</td>
<td>LDL-C &lt; 3.4mmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderately high: ≥ 2 risk factors and 10-year CHD risk 10 to &lt; 20%</td>
<td>LDL-C &lt; 3.4mmol/L (optional goal: &lt; 2.6mmol/L)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>High: CHD equivalent or 10-year CHD risk &gt; 20%</td>
<td>LDL-C &lt; 2.6mmol/L (optional goal: &lt; 1.8mmol/L for very high risk)</td>
<td></td>
</tr>
<tr>
<td>JBS2 (2005)</td>
<td>High: 10-year CVD risk ≥ 20%</td>
<td>Optimal targets: LDL-C &lt; 2.0mmol/L and TC &lt; 4.0mmol/L, or 30% LDL-C reduction and 25% TC reduction Audit (minimum) standard: LDL-C &lt; 3.0mmol/L and TC &lt; 5.0mmol/L</td>
<td>Prediction charts are commonly used as reference in public sectors</td>
</tr>
<tr>
<td>New Zealand (2012 and 2013)</td>
<td>For original recommendation21, optimal targets were recommended.</td>
<td>5-year CVD risk ≥ 15% LDL-C &lt; 2.0mmol/L, TC &lt; 4.0mmol/L, HDL-C ≥ 1.0mmol/L, TG &lt;1.7mmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subsequent update22 does not recommended specific targets.</td>
<td>TC ≥ 8mmol/L or TC:HDL-C ratio ≥ 8 Recommend drug treatment irrespective of CVD risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combined CVD risk &gt; 20%</td>
<td>Recommend drug treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combined CVD risk 10-20%</td>
<td>Shared decision-making approach on drug treatment</td>
<td></td>
</tr>
<tr>
<td>ACC/AHA (2013)</td>
<td>Recommends the use of high or moderate intensity statin in different risk. No recommendations on specific treatment targets.</td>
<td>Primary LDL-C ≥ 4.9mmol/L High intensity statin Age 40-75 years without diabetes and 10-year ASCVD risk ≥ 7.5% Moderate to high intensity statin</td>
<td>Remarks: Moderate-intensity statin: 30% to &lt; 50% LDL-C reduction. High-intensity statin: ≥ 50% LDL-C reduction</td>
</tr>
</tbody>
</table>

(Table continued on next page)
<table>
<thead>
<tr>
<th>Guideline</th>
<th>Risk Category</th>
<th>Lipid Target (if any)/ treatment strategies</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE (2014)17</td>
<td>High: 10-year CVD risk ≥ 10%</td>
<td>&gt; 40% non-HDL-C reduction</td>
<td>Fasting blood is not required for non-HDL-C</td>
</tr>
<tr>
<td></td>
<td>Moderate:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• SCORE ≥ 1% to &lt; 5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High:</td>
<td>LDL-C &lt; 3.0mmol/L</td>
<td></td>
</tr>
</tbody>
</table>
|                 | • markedly elevated single risk factors (e.g. familial dyslipidaemia, severe HT) or most other people with DM (some young people with type 1 diabetes may be at low or moderate risk) or • moderate CKD or • SCORE ≥ 5% to < 10% | LDL-C < 2.6mmol/L.  
≥ 50% reduction on LDL-C if baseline is between 2.6 and 5.1mmol/L |                                              |
|                 | Very high:                             | LDL-C < 1.8mmol/L.  
≥ 50% reduction on LDL-C if baseline is between 1.8 and 3.5 mmol/L |                                              |
|                 | • documented CVD or DM with target organ damage or • severe CKD or • SCORE ≥ 10% |                                             |                                              |

**Abbreviations:**

- ASCVD: Atherosclerotic cardiovascular disease
- CVD: Cardiovascular disease
- HT: Hypertension
- Non-HDL-C: Non high-density lipoprotein cholesterol
- CHD: Coronary heart disease
- DM: Diabetes mellitus
- HDL-C: High-density lipoprotein cholesterol
- LDL-C: Low-density lipoprotein cholesterol
- TC: Total cholesterol
- TG: Triglycerides
Management

Dyslipidaemia can be modified by dietary change, increase in physical activity and lipid lowering drugs. In case of any secondary causes of dyslipidaemia such as hypothyroidism, diabetes, liver disease, nephrotic syndrome or steroid treatment, they should be identified and treated accordingly. Lifestyle modification is recommended in all hypertensive patients with dyslipidaemia. Use of lipid lowering drugs should be commenced in patients who are considered having high cardiovascular risk or when lifestyle modification alone fails.

Lifestyle modification\textsuperscript{6,14}

- Reduction of dietary fat intake
- Total fat <30% of total calorie/day
- Saturated fat <7%, cholesterol <200 mg, trans fat <1% of total calorie intake/day

Drug treatment (Figure 1)

There are some patient groups who are more likely to discontinue their lipid-lowering medications after prescription. Recent studies performed in Hong Kong found that younger subjects (<50 years), patients who paid their first clinic visit and those without any comorbidities were more likely non-adherent or discontinuing their medications\textsuperscript{23,24}. These subjects should receive more meticulous monitoring of their medication-taking behaviour.

(1) \textit{Statins (HMG - CoA reductase inhibitors)}\textsuperscript{25-27}

- \(\downarrow\) LDL-C 25-55%, \(\downarrow\) TG 15-30%, \(\uparrow\) HDL-C 5-10%
- 25-55% risk reduction in cardiovascular diseases (coronary heart disease, stroke) in primary and secondary prevention studies
- Practical algorithm of statin usage is illustrated in Figure 1

(2) \textit{Fibrates}\textsuperscript{28}

- \(\downarrow\) TG 25-50% + \(\uparrow\) HDL-C 10-20%
- There is no strong evidence for using fibrate therapy in primary prevention of cardiovascular disease. The use of fibrates in these patients should only be considered when statins are contraindicated.
- Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis\textsuperscript{19}. Fenofibrate is the preferred agent when used in combination with statins but should be used with cautions and under close monitoring

(3) \textit{Ezetimibe}

- Can be used as an add-on drug in association with statins when the therapeutic target is not achieved at the maximum tolerated statin dose, or as an alternative to statins in patients who are intolerant of statins or with contraindications to statins\textsuperscript{4}
- No major adverse effects have been reported; the most frequent adverse effects are moderate elevations of liver enzymes and muscle pain\textsuperscript{14}
Figure 1. Practical algorithm of statin usage

Liver disease/ unexplained, persistent elevations of liver enzymes/ pregnant or lactating women

NO

Relative contraindications:
Concomitant use of cyclosporine, gemfibrozil, niacin, macrolide antibiotics, various antifungal agents, and cytochrome P-450 inhibitors

YES

Consider other treatment modalities

NO

Trade name of statins can be searched in https://www.drugoffice.gov.hk/eps/do/en/healthcare_providers/home.html

Starting dose:
Simvastatin 10mg nocte / Pravastatin 10mg note / Atorvastatin 10mg daily / Rosuvastatin 5mg daily / Lovastatin 10mg daily / Fluvastatin 20mg daily

LDL not reaching targets

On titration of statins
- Rule of Six: Doubling of dosage of statin will result in 6% LDL reduction but increased risk of transaminase elevation.

The following demonstrates the doubling of dosage of statin:

- **Simvastatin** 10mg → 20mg → 40mg
- **Pravastatin** 10mg → 20mg → 40mg
- **Atorvastatin** 10mg → 20mg → 40mg → 80mg
- **Rosuvastatin** 5mg → 10mg → 20mg
- **Lovastatin** 10mg → 20mg → 40mg
- **Fluvastatin** 20mg → 40mg → 80mg

See Notes on hepatic side effects of statins

If LDL does not reach targets despite titration of statin or side effects develop on higher doses of statin, consider referral to specialist for combination lipid lowering therapies with statin and other medications.

(Figure continued on next page)
Figure 1. Practical algorithm of statin usage (Continued)

**Muscle Soreness/Tenderness/Pain**
- Blood for CK only if muscle symptoms arise
- Increase in CK → Rule out common causes like Exercise / Strenuous work → Advise Moderation
- CK > 10x ULN → STOP
- CK 3-10x ULN + symptoms → STOP
- Progressive but asymptomatic CK elevation → Reduction in dose or temporary discontinuation

**Headache and Dyspepsia**
- Initial
- 6-8 weeks after therapy
- Each follow up

**Monitoring - Laboratory**
- Before start
- 12 weeks after start of statin
- Thereafter repeat if clinically indicated
- <3 x ULN → careful monitoring
- > =3 x ULN → STOP

**Monitoring - Symptoms**

**ALT/AST**
- Before start
- 12 weeks after start of statin
- Thereafter repeat if clinically indicated
- <3 x ULN → careful monitoring
- > =3 x ULN → STOP

**Abbreviations:**
- ALT: Alanine transaminase
- AST: Aspartate aminotransferase
- CK: Creatine kinase
- ULN: Upper limit of normal

**Notes on hepatic side effects of statin:**
- Elevated hepatic transaminase generally occurs in 0.5%-2% of cases and is dose dependent, with relative risk 2 – 4 fold at higher doses of statin
- Progression to liver failure specifically due to statin is exceedingly rare if ever occurs
- Reversal of transaminase elevation is frequently noted with a reduction in dose, and elevations do not often recur with either re-challenge or selection of another statin
**Simvastatin dose limitations**

When used with simvastatin, the following medications can raise the levels of simvastatin in the body and increase the risk of myopathy. Taking no more than the recommended dose of simvastatin with these medications will help keep simvastatin levels in the body at a safer level.

<table>
<thead>
<tr>
<th>New simvastatin label</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contraindicated with simvastatin:</td>
</tr>
<tr>
<td>• Itraconazole</td>
</tr>
<tr>
<td>• Ketoconazole</td>
</tr>
<tr>
<td>• Posaconazole (New)</td>
</tr>
<tr>
<td>• Erythromycin</td>
</tr>
<tr>
<td>• Clarithromycin</td>
</tr>
<tr>
<td>• Telithromycin</td>
</tr>
<tr>
<td>• HIV protease inhibitors</td>
</tr>
<tr>
<td>• Nefazodone</td>
</tr>
<tr>
<td>• Gemfibrozil</td>
</tr>
<tr>
<td>• Cyclosporine</td>
</tr>
<tr>
<td>• Danazol</td>
</tr>
</tbody>
</table>

| Do not exceed 10 mg simvastatin daily with: |
| • Verapamil |
| • Diltiazem |

| Do not exceed 20 mg simvastatin daily with: |
| • Amiodarone |
| • Amlodipine (New) |
| • Ranolazine (New) |

| Avoid large quantities of grapefruit juice (>1 quart daily) |

FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 15 Dec 2011.
Module 9  Lipid Management in Hypertensive Patients

Reference:


